###begin article-title 0
Hypoxia and TGF-beta Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment
###end article-title 0
###begin p 1
Conceived and designed the experiments: LKD KM PGJF JMC TG. Performed the experiments: LKD KM PGJF CRM HD MN XHP TG. Analyzed the data: LKD KM PGJF TG. Contributed reagents/materials/analysis tools: LKD PGJF JMC TG. Wrote the paper: LKD KM PGJF JMC TG.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 5 13 <span type="species:ncbi:9606">patients</span>
Most patients with advanced breast cancer develop bone metastases, which cause pain, hypercalcemia, fractures, nerve compression and paralysis. Chemotherapy causes further bone loss, and bone-specific treatments are only palliative. Multiple tumor-secreted factors act on the bone microenvironment to drive a feed-forward cycle of tumor growth. Effective treatment requires inhibiting upstream regulators of groups of prometastatic factors. Two central regulators are hypoxia and transforming growth factor (TGF)- beta. We asked whether hypoxia (via HIF-1alpha) and TGF-beta signaling promote bone metastases independently or synergistically, and we tested molecular versus pharmacological inhibition strategies in an animal model.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
We analyzed interactions between HIF-1alpha and TGF-beta pathways in MDA-MB-231 breast cancer cells. Only vascular endothelial growth factor (VEGF) and the CXC chemokine receptor 4 (CXCR4), of 16 genes tested, were additively increased by both TGF-beta and hypoxia, with effects on the proximal promoters. We inhibited HIF-1alpha and TGF-beta pathways in tumor cells by shRNA and dominant negative receptor approaches. Inhibition of either pathway decreased bone metastasis, with no further effect of double blockade. We tested pharmacologic inhibitors of the pathways, which target both the tumor and the bone microenvironment. Unlike molecular blockade, combined drug treatment decreased bone metastases more than either alone, with effects on bone to decrease osteoclastic bone resorption and increase osteoblast activity, in addition to actions on tumor cells.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
Hypoxia and TGF-beta signaling in parallel drive tumor bone metastases and regulate a common set of tumor genes. In contrast, small molecule inhibitors, by acting on both tumor cells and the bone microenvironment, additively decrease tumor burden, while improving skeletal quality. Our studies suggest that inhibitors of HIF-1alpha and TGF-beta may improve treatment of bone metastases and increase survival.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 180 183 180 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Roodman1">[1]</xref>
###xml 400 403 400 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Roodman1">[1]</xref>
###xml 1012 1015 1006 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Mundy1">[2]</xref>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
Breast cancers frequently metastasize to bone, where they disrupt normal bone remodeling to cause bone destruction, pain, pathologic fracture, hypercalcemia, and nerve compression [1]. Besides conventional radiation and chemotherapy, bisphosphonates are the only treatment available for patients with bone metastases. These drugs decrease skeletal morbidity and provide palliative relief but no cure [1]. Bone is a unique microenvironment in which breast cancer thrives. Growth factors, such as transforming growth factor-beta (TGF- beta) are stored in the mineralized bone matrix. Breast cancers that metastasize to bone secrete factors, such as parathyroid hormone-related protein (PTHrP) and interleukin-11 (IL-11), that stimulate osteoclastic bone destruction and the release and activation of growth factors immobilized in the bone matrix. These factors in turn act on tumor cells to promote a feed-forward cycle of tumor growth and bone destruction which contributes to the incurability of bone metastases [2]. Hypoxia and high concentrations of TGF-beta in the bone microenvironment enhance tumor production of factors that drive the feed-forward cycle of bone metastasis. We asked whether the hypoxia and TGF-beta signaling pathways have additive or synergistic effects to promote breast cancer bone metastasis to determine if combined treatment with inhibitors of these pathways could be used to treat bone metastases.
###end p 9
###begin p 10
###xml 263 266 254 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Massague1">[3]</xref>
###xml 460 463 433 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Massague1">[3]</xref>
###xml 772 775 742 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Massague2">[4]</xref>
Bone is the largest storehouse of TGF-beta in the body. TGF-beta has complex effects in cancer and is a growth suppressor early in tumorigenesis; however, many advanced cancers escape from growth inhibition by TGF-beta and express prometastatic genes in response [3]. TGF-beta signaling pathway is activated when TGF-beta binds to the TGF-beta type II receptor (TbetaRII) and promotes dimerization with and activation of the TGF-beta type I receptor (TbetaRI) [3]. TbetaRI contains a kinase domain which phosphorylates the receptor-associated Smads, Smad2 and Smad3. These factors bind to Smad4 forming a heteromeric Smad complex which translocates to the nucleus and mediates gene transcription by binding to Smad binding elements (SBEs) in the promoters of target genes [4].
###end p 10
###begin p 11
###xml 167 170 164 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Chiang1">[5]</xref>
###xml 172 179 169 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006896-t001">Table 1</xref>
###xml 196 199 193 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Yin1">[6]</xref>
###xml 297 300 294 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Kakonen1">[7]</xref>
###xml 301 305 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Bendre2">[10]</xref>
###xml 527 530 518 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Yin1">[6]</xref>
###xml 662 665 650 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Yin1">[6]</xref>
###xml 722 726 707 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Deckers1">[11]</xref>
###xml 728 732 713 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Kang2">[12]</xref>
###xml 773 777 758 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Javelaud1">[13]</xref>
###xml 838 842 823 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Ge1">[14]</xref>
###xml 924 928 903 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Bandyopadhyay1">[15]</xref>
###xml 929 933 908 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Hayashi1">[18]</xref>
###xml 330 335 <span type="species:ncbi:10090">mouse</span>
TGF-beta has an additional role in cancer to promote bone metastasis by regulating many of the tumor-secreted factors that stimulate tumor growth and bone destruction [5] (Table 1), such as PTHrP [6], IL-11, connective tissue growth factor (CTGF), the CXC chemokine receptor 4 (CXCR4), and others [7]-[10]. Previous studies using mouse models have shown that blockade of TGF-beta signaling in MDA-MB-231 breast carcinoma cells by stable expression of a dominant-negative TbetaRII reduced bone metastases and increased survival [6]. Expression of a constitutively active TbetaRI reversed this effect, resulting in increased bone metastases and decreased survival [6]. Inhibition of TGF-beta signaling by knockdown of Smad4 [11], [12], overexpression of the inhibitory Smad7 [13], or treatment with pharmacologic inhibitors, such as SD-208 [14], an ATP-competitive inhibitor of the TbetaRI kinase or other TGF-beta inhibitors [15]-[18] decreased bone metastases in animal models.
###end p 11
###begin title 12
Regulation of bone metastases genes by hypoxia and TGF-beta.
###end title 12
###begin p 13
###xml 162 163 159 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
Number of hits returned from a Pubmed literature search conducted in February 2009 for the name of each gene with the keywords TGF-beta and/or hypoxia. Asterisk (*) indicates genes for which regulation by these pathways has been published.
###end p 13
###begin p 14
###xml 38 39 38 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 54 58 54 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Hirao1">[19]</xref>
###xml 153 154 153 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 300 304 300 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Harris1">[20]</xref>
###xml 427 431 427 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Brown1">[21]</xref>
###xml 653 657 645 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Zhong1">[22]</xref>
###xml 947 951 928 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Harris1">[20]</xref>
###xml 953 957 934 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Semenza1">[23]</xref>
Bone is a hypoxic microenvironment (pO2 between 1-7%) [19], which increases growth of metastatic tumor cells adapted for surviving in conditions of low O2. Breast cancers and other solid tumors are susceptible to hypoxia because they proliferate and outgrow vascular supplies of oxygen and nutrients [20]. Tumor hypoxia causes radio- and chemotherapeutic resistance, which may contribute to the incurability of bone metastases [21]. Hypoxia activates signaling through hypoxia-inducible factor (HIF)-1alpha, which is overexpressed in many cancers, including breast. HIF-1alpha expression correlates with increasing tumor grade, invasion, and metastasis [22]. In conditions of high oxygen, HIF-1alpha is hydroxylated and targeted for proteasomal degradation by the von Hippel Lindau tumor suppressor. When oxygen is limiting, HIF-1alpha heterodimerizes with HIF-1beta in the nucleus and mediates the transcription of hypoxia-regulated target genes [20], [23].
###end p 14
###begin p 15
###xml 89 96 86 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006896-t001">Table 1</xref>
###xml 134 139 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 240 243 237 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Kang1">[8]</xref>
###xml 245 249 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Javelaud1">[13]</xref>
###xml 251 255 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Duivenvoorden1">[24]</xref>
###xml 256 260 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Ao1">[26]</xref>
###xml 763 767 753 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Ge1">[14]</xref>
###xml 769 773 759 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Bandyopadhyay1">[15]</xref>
###xml 775 779 765 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-LaVallee1">[27]</xref>
###xml 780 784 770 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Uhl1">[31]</xref>
Many bone metastases genes that are regulated by TGF-beta are also regulated by hypoxia (Table 1), including those identified by Kang et al. to comprise a bone-metastatic gene signature in breast cancer cells: CTGF, CXCR4, IL-11, and MMP-1 [8], [13], [24]-[26]. These genes code for proteins that regulate different steps of the metastatic cascade: invasion, homing, angiogenesis and osteolysis. Breast cancer cells express there and many other prometastatic genes. Thus, therapeutic targeting of individual proteins is unlikely to cure breast cancer bone metastases. Inhibitors of HIF-1alpha or TGF-beta, which act upstream of multiple target genes, may be more effective and several are under investigation in phase I and II clinical trials for various cancers [14], [15], [27]-[31].
###end p 15
###begin p 16
###xml 81 89 78 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 456 464 444 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 513 520 501 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 662 669 647 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 552 557 <span type="species:ncbi:10090">mouse</span>
###xml 767 776 <span type="species:ncbi:10090">nude mice</span>
###xml 1227 1231 <span type="species:ncbi:10090">mice</span>
###xml 1928 1932 <span type="species:ncbi:10090">mice</span>
We investigated interactions between the hypoxia and TGF-beta signaling pathways in vitro by examining bone-metastatic MDA-MB-231 breast cancer cells for changes in TGF-beta and hypoxia-stimulated gene expression of 16 candidate genes. Of these, only vascular endothelial growth factor (VEGF) and CXCR4, showed additive responses to TGF-beta and hypoxia, suggesting limited crosstalk between TGF-beta and hypoxia signaling pathways in breast cancer cells. In vitro analyses, however, may not accurately represent in vivo function. Therefore, we used a mouse model of bone metastasis to assess global crosstalk between the hypoxia and TGF-beta signaling pathways in vivo. In this model, the MDA-MB-231 breast cancer cell line reliably forms osteolytic bone lesions in nude mice when inoculated into the left cardiac ventricle. We tested the effects TGF-beta and hypoxia on bone metastases in this model by genetic and pharmacologic approaches. In the first approach, we used genetic methods of shRNA knockdown and dominant-negative expression to specifically target the tumor cells. Genetic inhibition of HIF-1alpha and TGF-beta signaling pathways in MDA-MB-231 cells significantly decreased osteolysis and enhanced survival of mice with bone metastases. Combined inhibition of HIF-1alpha and TGF-beta in the tumor cells had no additional effect, suggesting parallel roles for hypoxia and TGF-beta signaling in tumor cells. This approach provided proof of principle for the tumor autonomous effects of HIF-1alpha and TGF-beta signaling in bone metastases, but it is not readily translatable to the clinic. In a second pharmacologic approach, we inhibited HIF-1alpha and TGF-beta signaling systemically using small molecule inhibitors to target both the tumor cells and the bone microenvironment. Inhibition of HIF-1alpha or TGF-beta with these inhibitors also decreased osteolysis, reduced tumor burden, and enhanced survival of mice with bone metastases. In contrast to the genetic models, combined pharmacologic inhibition produced an additional decrease in tumor burden compared to either alone. Systemic inhibition of HIF-1alpha and TGF-beta signaling also had independent effects on bone to decrease osteoclast and increase osteoblast activity. Thus, combined systemic inhibition of HIF-1alpha and TGF-beta signaling is more beneficial than either alone due to activity on the tumor cells and the bone microenvironment.
###end p 16
###begin title 17
Results
###end title 17
###begin title 18
Hypoxia induces HIF-1alpha expression in bone metastatic cancer cell lines in vitro and in vivo at sites of MDA-MB-231 breast cancer bone metastases
###end title 18
###begin p 19
###xml 180 181 180 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 368 372 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Mabjeesh1">[32]</xref>
###xml 373 377 365 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Zhou1">[34]</xref>
###xml 379 388 371 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g001">Figure 1A</xref>
###xml 471 478 463 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 515 519 498 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Raleigh1">[35]</xref>
###xml 520 524 503 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Carmeliet1">[38]</xref>
###xml 785 794 768 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g001">Figure 1B</xref>
###xml 526 530 <span type="species:ncbi:10090">Mice</span>
###xml 752 756 <span type="species:ncbi:10090">mice</span>
Three bone metastatic cancer cell lines: MDA-MB-231 breast cancer, PC-3 prostate cancer, and 1205Lu melanoma cells, were tested for hypoxic responsiveness by culture in 20% or 1% O2 for 6 h. Western blot analysis showed induction of HIF-1alpha expression under hypoxic conditions, which was blocked by treatment with the HIF-1alpha inhibitor 2-methoxyestradiol (2ME2) [32]-[34] (Figure 1A). We next determined whether MDA-MB-231 breast cancer bone metastases are hypoxic in vivo by Hypoxyprobetrade mark-1 staining [35]-[38]. Mice with MDA-MB-231 bone metastases were injected 2 h prior to euthanasia with pimonidazole, which forms insoluble protein adducts in hypoxic cells. Staining was detected in bone metastases sections from pimonidazole-labeled mice but not in control animals (Figure 1B). Staining for HIF-1alpha protein was detected in serial bone metastases sections, at sites adjacent to pimonidazole-positive hypoxic regions. The results suggest a role for hypoxia-induced HIF-1alpha in bone metastases.
###end p 19
###begin title 20
###xml 59 67 55 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 91 98 87 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Hypoxia induces HIF-1alpha in bone-metastatic cancer cells in vitro and in bone metastases in vivo.
###end title 20
###begin p 21
###xml 82 83 80 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 378 380 368 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 299 303 <span type="species:ncbi:10090">mice</span>
(A) MDA-MB-231, PC-3 and 1205Lu cells were treated with 2ME2 and cultured +/- 1% O2 during 6 h. Protein lysates from the treated cells were analyzed for HIF-1alpha protein expression by Western blotting. alpha-tubulin was used as loading control. (B) Representative demineralized bone sections from mice with MDA-MB-231 bone metastases stained for tumor hypoxia with HypoxyprobeTM-1 (HP), with an antibody against HIF-1alpha, or with hematoxylin and eosin (H&E). Arrows indicate HIF-1alpha positive nuclei. Images are at 200xmagnification with scale bar equal to 100 microm, inset is at 630xmagnification with scale bar equal to 50 microm. Staining without primary antibody was used as negative control.
###end p 21
###begin title 22
Hypoxia and TGF-beta additively increase prometastatic factors VEGF and CXCR4
###end title 22
###begin p 23
###xml 146 153 143 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006896-t001">Table 1</xref>
###xml 217 218 207 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 370 377 357 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006896-t001">Table 1</xref>
###xml 752 753 726 727 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 761 770 735 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g002">Figure 2A</xref>
###xml 839 840 810 811 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1177 1181 1145 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Akagi1">[39]</xref>
###xml 1224 1228 1192 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Caruz1">[40]</xref>
###xml 1230 1234 1198 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Phillips1">[41]</xref>
###xml 1244 1245 1212 1213 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sub>
###xml 1479 1481 1437 1439 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2.</sub>
###xml 1577 1586 1532 1541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g002">Figure 2B</xref>
###xml 1671 1672 1626 1627 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sub>
###xml 1148 1153 <span type="species:ncbi:9606">human</span>
###xml 1194 1199 <span type="species:ncbi:9606">human</span>
A literature search for bone metastatic genes combined with the keywords hypoxia or TGF-beta, found that many were regulated by the two pathways (Table 1). MDA-MB-231 cells treated +/- TGF-beta1 (5 ng/mL) and +/- 1% O2 for 24 h were then surveyed by semi-quantitative RT-PCR for changes in mRNA expression of candidate TGF-beta and hypoxia-regulated genes selected from Table 1: VEGF; CXCR4; PTHrP; IL-6, 8, 11; and CTGF. We also measured the expression of components of the two signaling pathways: HIF-1alpha, prolyl hydroxylase 2 (PHD2), TGF-beta1, Smads2, 3, 4 and 7, Ski and SnoN. Many genes were increased by TGF-beta or hypoxia alone (data not shown) while only 2 of the 16 surveyed genes, VEGF and CXCR4, were increased by both TGF-beta and 1% O2 alone (Figure 2A). VEGF mRNA expression was additively increased by TGF-beta and 1% O2; however, there was no additional increase in CXCR4 mRNA expression with combined treatment. Transcriptional activation of the VEGF and CXCR4 promoters by TGF-beta and hypoxia was analyzed by dual-luciferase assay in HepG2 cells transfected with a pGL3-luciferase reporter vector containing either a 3.3 kb human VEGF promoter fragment [39] or a 2.6 kb human CXCR4 promoter fragment [40], [41]. A (CAGA)9 promoter-luciferase construct containing nine tandemly-repeated Smad-binding elements (SBEs) was used as positive control for TGF-beta activation. Dual-luciferase activity was assayed after a 24 h-treatment +/- TGF-beta1 and +/- 1% O2. VEGF and CXCR4 promoter activities were increased by treatment with TGF-beta or hypoxia alone (Figure 2B). Combined treatment additively increased VEGF and CXCR4 promoter activation. (CAGA)9 promoter activity was increased only by treatment with TGF-beta, demonstrating that hypoxia does not directly regulate TGF-beta/Smad signaling. These results suggest that crosstalk between the hypoxia and TGF-beta signaling pathways regulates VEGF and CXCR4 mRNA expression and promoter activation.
###end p 23
###begin title 24
Hypoxia and TGF-beta increase VEGF and CXCR4 mRNA expression and promoter activity.
###end title 24
###begin p 25
###xml 66 67 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 207 209 198 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 219 221 210 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 233 235 224 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 498 499 486 487 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sub>
###xml 557 558 538 539 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 875 876 845 846 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1021 1022 989 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1032 1033 1000 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1044 1045 1012 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1058 1059 1026 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 365 368 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 418 423 <span type="species:ncbi:9606">human</span>
###xml 701 706 <span type="species:ncbi:9606">human</span>
###xml 743 746 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(A) MDA-MB-231 cells were cultured +/- TGF-beta (5 ng/mL) +/- 1% O2 during 24 h and total RNA was extracted. VEGF and CXCR4 mRNA expression (mean +/- SEM) was measured by semi-quantitative RT-PCR (n = 3). * P<0.05, *** P<0.005, **** P<0.001, using an unpaired Student's t test. (B) HepG2 hepatocarcinoma cells co-transfected with a renilla luciferase plasmid (phRL-CMV) and a pGL3 plasmid containing a fragment of the human VEGF (3.3 kb) or CXCR4 (2.6 kb) promoter, or the TGF-beta-sensitive (CAGA)9 promoter were treated +/- TGF-beta (5 ng/mL) and +/- 1% O2 during 24 h before measuring dual-luciferase activity. (C) MDA-MB-231 breast cancer cells were transfected with a pGL3 plasmid containing the human VEGF or CXCR4 promoter and the phRL-CMV plasmid, as well as plasmids to overexpress HIF-1alpha and/or Smad2, 3 and 4. Cells were treated +/- TGF-beta (5 ng/mL) +/- 1% O2 during 24 h before measuring dual-luciferase activity. Results are expressed as the mean +/- SEM (n = 3) of the relative luciferase activity. * P<0.05, ** P<0.01, *** P<0.005, **** P<0.001, using an unpaired Student's t test.
###end p 25
###begin title 26
Overexpression of HIF-1alpha and Smads increases VEGF and CXCR4 expression
###end title 26
###begin p 27
###xml 336 337 322 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 464 473 443 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g002">Figure 2C</xref>
Next we tested whether HIF-1alpha and Smads mediate promoter activation in response to hypoxia and TGF-beta. HIF-1alpha or Smads2, 3, and 4 were overexpressed in MDA-MB-231 cells cotransfected with either the VEGF or CXCR4 promoter-luciferase plasmids. Dual-luciferase activity was assayed after a 24 h-treatment with TGF-beta1 and 1% O2. Overexpression of either HIF-1alpha or Smads increased VEGF and CXCR4 promoter activity in response to TGF-beta and hypoxia (Figure 2C). Coexpression of HIF-1alpha and Smads together resulted in a 10-fold increase in VEGF and CXCR4 promoter activities in the presence of TGF-beta and hypoxia, suggesting that VEGF and CXCR4 transcriptional responses to hypoxia and TGF-beta are mediated through HIF-1alpha and Smads, respectively.
###end p 27
###begin title 28
TGF-beta and hypoxia interact to regulate VEGF and CXCR4 transcription
###end title 28
###begin p 29
###xml 438 447 429 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g003">Figure 3A</xref>
To identify promoter regions targeted by TGF-beta and hypoxia signaling, constructs with 5'-deletion of the promoter, ranging in size from 3.3 kb to 1.8 kb for VEGF and 2.6 kb to 1.0 kb for CXCR4, were tested for TGF-beta and hypoxia responsiveness by dual-luciferase assay. VEGF promoter response to TGF-beta and hypoxia was blocked by deletion of bases -1181 to -843, while deletion of bases -2216 to -953 blocked CXCR4 responsiveness (Figure 3A). These results suggest that transcriptional activation by TGF-beta and hypoxia is localized within 300 base pairs in the VEGF promoter and in a 1.2 kb region for CXCR4.
###end p 29
###begin title 30
Hypoxia and TGF-beta increase VEGF and CXCR4 transcription through proximal promoter response elements.
###end title 30
###begin p 31
###xml 212 213 205 206 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 843 844 827 828 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1034 1035 1016 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1045 1046 1027 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1057 1058 1039 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1071 1072 1053 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 107 112 <span type="species:ncbi:9606">human</span>
###xml 149 152 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 780 783 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(A) HepG2 cells were transfected with pGL3 plasmids containing full-length for 5'-deleted fragments of the human VEGF or CXCR4 promoter and the phRL-CMV plasmid. Cells were treated +/- TGF-beta (5 ng/mL) +/- 1% O2 during 24 h before measuring dual-luciferase activity. Results are expressed as the mean +/- SEM (n = 3) of the relative luciferase activity, analyzed using an unpaired Student's t test. (B) Schematic representation of wild-type (WT), HRE-mutant (mH1) and SBE-mutant (mS1 or mS2) VEGF and CXCR4 promoters. One to three nucleotides (underlined, bold letters) within HRE and SBEs were substituted as indicated. (C) HepG2 cells were transfected with pGL3 plasmids containing a wild-type VEGF or CXCR4 promoter or promoters with mutations to the HRE or SBE and the phRL-CMV plasmid. Cells were treated +/- TGF-beta (5 ng/mL) +/- 1% O2 during 24 h before measuring dual-luciferase activity. Results are expressed as the mean +/- SEM (n = 3) of the relative luciferase activity, analyzed using an unpaired Student's t test. * P<0.05, ** P<0.01, *** P<0.005, **** P<0.001.
###end p 31
###begin p 32
###xml 117 127 117 127 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-RCGTG-3</named-content>
###xml 133 144 133 144 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CAGAC-3&#8242;</named-content>
###xml 287 296 287 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g003">Figure 3B</xref>
###xml 501 502 495 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 504 513 498 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g003">Figure 3C</xref>
###xml 765 774 756 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g003">Figure 3C</xref>
Promoter sequences were scanned for putative hypoxia response elements (HREs) and SBEs using the consensus sequences 5'-RCGTG-3' and 5'-CAGAC-3', respectively. HREs and SBEs found in close proximity within the promoter regions identified above were mutated by site-directed mutagenesis (Figure 3B). TGF-beta and hypoxia responsiveness were assayed using dual-luciferase. In the VEGF promoter, mutation of HRE (-975/-970) and SBEs (-992/-988) and (-797/-793) decreased the response to TGF-beta and 1% O2 (Figure 3C). The combined mutation of the HRE and one of the SBE nearly abolished promoter activity. Mutation of HRE (-1316/-1310) in the CXCR4 promoter blocked additive responses to TGF-beta and hypoxia, while mutation of putative SBEs had little or no effect (Figure 3C). These data suggest that both TGF-beta and hypoxia regulate VEGF promoter activity, while only hypoxia regulates CXCR4 promoter activity. The promoter may contain additional non-identified SBEs that mediate its response to TGF-beta.
###end p 32
###begin title 33
###xml 119 124 <span type="species:ncbi:10090">mouse</span>
HIF-1alpha knockdown in MDA-MB-231 breast cancer cells decreases osteolytic bone metastases and improves survival in a mouse model
###end title 33
###begin p 34
###xml 58 66 58 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 463 472 447 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g004">Figure 4A</xref>
###xml 717 718 694 695 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 885 894 859 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g004">Figure 4B</xref>
###xml 941 950 915 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g004">Figure 4C</xref>
###xml 1000 1009 974 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g004">Figure 4D</xref>
We further examined hypoxic responses of MDA-MB-231 cells in vitro by stable knockdown of HIF-1alpha. The cells were transfected with a plasmid expressing an shRNA targeting HIF-1alpha. Single cell clones were isolated and stability of the knockdown was tested after cultivating the cells for 60 days in absence of antibiotic. Two clones (shHIF#3 and #11) with >90% decrease of HIF-1alpha mRNA and undetectable levels of HIF-1alpha protein were further analyzed (Figure 4A). Two control shRNA clones (shNT#3 and #7) had HIF-1alpha mRNA expression similar to parental cells and were used as controls. The clones were also analyzed by semi-quantitative RT-PCR for changes in mRNA expression following TGF-beta1 and 1% O2 treatment for 24 h. TGF-beta- and hypoxia-induced VEGF and CXCR4 mRNA expression was significantly decreased in the shHIF clones compared to parental and shNT cells (Figure 4B). Secreted VEGF-A protein, measured by ELISA (Figure 4C), and CXCR4 protein, measured by flow cytometry (Figure 4D), were also decreased. The results demonstrate that knockdown of HIF-1alpha blocks expression of prometastatic factors VEGF and CXCR4 in MDA-MB-231 cells. An MTT assay showed no difference in proliferation for any of the shHIF or shNT clones compared to parental MDA-MB-231 cells in normoxic conditions. Proliferation of each clone was decreased by culture in hypoxic compared to normoxic conditions; however, there was no difference among the clones (data not shown).
###end p 34
###begin title 35
###xml 76 84 72 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Knockdown of HIF-1alpha inhibits VEGF and CXCR4 mRNA and protein expression in vitro.
###end title 35
###begin p 36
###xml 193 194 187 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 468 469 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 605 606 578 579 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 739 741 710 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 750 752 721 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 763 765 734 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 897 898 861 862 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1053 1054 1015 1016 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1067 1069 1029 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1178 1179 1138 1139 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
(A) MDA-MB-231 parental cells (P) or cells transfected with a pLKO.1 vector expressing a non-target shRNA (shNT#3 and #7) or an shRNA against HIF-1alpha (shHIF#3 and #11) were cultured +/- 1% O2 during 6 h. Total RNA was extracted and mean +/- SEM expression of HIF-1alpha was measured using semi-quantitative RT-PCR (n = 3). Proteins were extracted from treated cells and HIF-1alpha level was assayed by Western-blotting, alpha-tubulin was used as loading control. * P<0.05, using an unpaired Student's t test. (B) Parental (P) cells and shNT and shHIF clones were treated +/- TGF-beta (5 ng/mL) +/- 1% O2 for 24 h. Total RNA was extracted and mean +/- SEM VEGF and CXCR4 expression was measured using semi-quantitative RT-PCR (n = 3). * P<0.05, ** P<0.01, **** P<0.001, using an unpaired Student's t test. (C) MDA-MB-231 parental (P) cells and clones were treated +/- TGF-beta (5 ng/mL) +/- 1% O2 and conditioned media were collected 24 h later. VEGF-A levels were measured by ELISA assay. Results are expressed as mean +/- SEM nanograms VEGF-A per 106 cells. **** P<0.001, using an unpaired Student's t test. (D) MDA-MB-231 parental (P) cells and clones were treated +/- 1% O2 for 24 h and then analyzed by flow cytometry for CXCR4 protein expression. Results are reported as the percentage of maximal CXCR4 expression.
###end p 36
###begin p 37
###xml 45 52 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 489 491 481 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 513 515 505 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 571 582 563 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g005">Figure 5A&#8211;B</xref>
###xml 705 714 693 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g005">Figure 5C</xref>
###xml 990 1001 978 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g005">Figure 5D&#8211;E</xref>
###xml 61 66 <span type="species:ncbi:10090">mouse</span>
###xml 100 109 <span type="species:ncbi:10090">nude mice</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 671 675 <span type="species:ncbi:10090">mice</span>
###xml 901 905 <span type="species:ncbi:10090">mice</span>
###xml 1060 1064 <span type="species:ncbi:10090">mice</span>
###xml 1110 1114 <span type="species:ncbi:10090">mice</span>
We tested the effect of HIF-1alpha knockdown in vivo using a mouse model of bone metastases. Female nude mice (4 weeks old) were inoculated in the left cardiac ventricle with parental MDA-MB-231 cells or one of the four different clones: shNT#3 and #7 controls, or shHIF#3 and #11 HIF-1alpha knockdown clones (n = 12 per group). Osteolytic lesion area on x-ray was decreased in mice with shHIF knockdown bone metastases compared to those with controls of parental or shNT bone metastases (P<0.001 for shHIF#3 and P<0.01 for shHIF#11 compared to parental or shNT clones) (Figure 5A-B). HIF-1alpha knockdown in bone metastatic cells also significantly improved survival of mice compared to control animals (Figure 5C). A secondary endpoint for this survival experiment was tumor burden, which was analyzed by quantitative histomorphometry. We observed no difference in tumor burden at time of death for mice with shHIF bone metastases compared to those with parental or shNT bone metastases (Figure 5D-E). We were unable to statistically compare tumor burden in mice from these groups at the same time point, as mice with shHIF bone metastases lived longer than the parental or shNT controls.
###end p 37
###begin title 38
###xml 83 90 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Knockdown of HIF-1alpha decreases osteolytic lesions and improves survival of mice in vivo.
###end title 38
###begin p 39
###xml 358 360 351 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 371 373 364 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 524 526 517 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 583 585 571 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 609 613 585 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&#8202;=&#8202;</italic>
###xml 1027 1031 997 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N.S.</italic>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
###xml 323 328 <span type="species:ncbi:10090">mouse</span>
###xml 506 511 <span type="species:ncbi:10090">mouse</span>
(A) Representative x-ray images from hindlimbs of mice 4 weeks post inoculation with MDA-MB-231 parental, shNT and shHIF cells. Arrows indicate osteolytic lesions. (B) Osteolytic lesion area measured on radiographs of hindlimbs and forelimbs of mice with bone metastases. Results are expressed as the mean area +/- SEM per mouse (n = 5-10 per group). dagger P<0.01 and * P<0.001 compared to parental or shNT clones using a two-way ANOVA with a Bonferroni post-test at 4 weeks. (C) Kaplan-Meyer analysis of mouse survival. * P<0.05 shHIF#3 compared to Parental or shNT clones, dagger P<0.005 and double dagger P = 0.089 shHIF#11 respectively compared to Parental and shNT#7 using a Logrank test. (D) Representative histology of femurs with tumor indicated by arrows. Scale bar equal to 500 microm. (E) Tumor burden in hindlimbs was measured by quantitative histomorphometry. Results are expressed as the mean +/- SEM area per bone. A one-way ANOVA with a Newman-Keuls multiple comparison test showed no significant differences (N.S.) between groups.
###end p 39
###begin p 40
###xml 201 208 193 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 221 233 213 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g006">Figures 6A&#8211;B</xref>
###xml 263 271 251 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 372 379 360 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 563 574 551 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g007">Figure 7A&#8211;B</xref>
Staining for HIF-1alpha in bone metastases tumor sections was decreased in shHIF bone metastases compared to parental and shNT controls, confirming the stability of HIF-1alpha knockdown throughout the in vivo experiment (Figures 6A-B). Since HIF-1alpha knockdown in vitro resulted in decreased mRNA expression of the angiogenic factor VEGF, we analyzed tumor angiogenesis in vivo by staining for the endothelial cell marker CD31. The number of vessels/tumor area was significantly decreased in shHIF bone metastases compared to parental and shNT bone metastases (Figure 7A-B). These data suggest that knockdown of HIF-1alpha in tumor cells decreases bone metastases by suppressing tumor secretion of proangiogenic factors and blocking vessel formation.
###end p 40
###begin title 41
###xml 54 61 50 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Knockdown of HIF-1alpha in MDA-MB-231 cells is stable in vivo.
###end title 41
###begin p 42
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 419 424 <span type="species:ncbi:10090">mouse</span>
(A) Representative HIF-1alpha staining in demineralized bone sections from mice inoculated with MDA-MB-231 parental, shNT or shHIF cells. Arrows indicate HIF-1alpha positive nuclei. Scale bar equals 50 microm. Staining without primary antibody was used as negative control (Neg. Control). (B) The percentage of nuclei positive for HIF-1alpha was calculated in three non-overlapping fields at 400xmagnification for each mouse (n = 3 per group). Results are the mean +/- SEM number of HIF-1alpha positive nuclei per field.
###end p 42
###begin title 43
###xml 81 85 <span type="species:ncbi:10090">mice</span>
HIF-1alpha knockdown decreases tumor angiogenesis at sites of bone metastases in mice.
###end title 43
###begin p 44
###xml 379 381 373 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 390 392 384 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 403 405 397 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 277 282 <span type="species:ncbi:10090">mouse</span>
(A) Representative sections from mice with bone metastases stained for the endothelial cell marker CD31. Arrows indicate CD31+ vessels. Scale bar equals 50 microm (B) The number of vessels in bone metastases was counted in three non-overlapping fields at 200xmagnification per mouse (n = 3 per group). Results are expressed as the mean +/- SEM number of vessel per tumor area. * P<0.05, ** P<0.01, **** P<0.001, using a one-way ANOVA with a Newman-Keuls multiple comparison test.
###end p 44
###begin title 45
HIF-1alpha knockdown or TGF-beta blockade in tumor cells reduces bone metastases and improves survival in vivo
###end title 45
###begin p 46
###xml 112 119 105 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 400 411 382 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g008">Figure 8A&#8211;B</xref>
###xml 533 542 512 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g008">Figure 8C</xref>
###xml 564 565 543 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sub>
###xml 611 620 587 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g008">Figure 8D</xref>
###xml 640 641 613 614 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 755 764 728 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g008">Figure 8E</xref>
###xml 767 774 740 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 1176 1183 1138 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1578 1580 1533 1535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1629 1631 1584 1586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1665 1676 1620 1631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g009">Figure 9A&#8211;B</xref>
###xml 1893 1902 1834 1843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g009">Figure 9C</xref>
###xml 2243 2252 2184 2193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g009">Figure 9D</xref>
###xml 776 780 <span type="species:ncbi:10090">mice</span>
###xml 898 902 <span type="species:ncbi:10090">mice</span>
###xml 1192 1201 <span type="species:ncbi:10090">nude mice</span>
###xml 1380 1384 <span type="species:ncbi:10090">Mice</span>
###xml 1795 1799 <span type="species:ncbi:10090">mice</span>
###xml 2156 2160 <span type="species:ncbi:10090">mice</span>
###xml 2310 2314 <span type="species:ncbi:10090">mice</span>
To evaluate the effect of single and combined inhibition of HIF-1alpha and TGF-beta specifically in tumor cells in vivo, we generated a series of MDA-MB-231 cell lines which stably expressed either HIF-1alpha shRNA alone or in combination with a dominant-negative TGF-beta type II receptor (DNRII). Knockdown of HIF-1alpha mRNA and protein was confirmed by semi-quantitative RT-PCR and Western blot (Figure 8A-B). Blockade of TGF-beta signaling in the DNRII expressing clones was confirmed by decreased phosho-Smad2 on Western blot (Figure 8C) and decreased (CAGA)9 promoter activation in response to TGF-beta (Figure 8D). TGF-beta and 1% O2-stimulated VEGF and CXCR4 mRNAs were decreased in the DNRII and DNRII/shHIF clones compared to parental control (Figure 8E). In vivo, mice inoculated with the DNRII/shHIF-1alpha clones had decreased osteolytic lesion area and improved survival compared to mice with bone metastases caused by parental or DNRII cell lines (data not shown). DNRII/shHIF#22 and DNRII/shNT#2 control clones were selected for a subsequent experiment in which we directly compared the effect of HIF-1alpha knockdown alone or combined with TGF-beta blockade in vivo. Female nude mice (n = 12 per group) were inoculated in the left cardiac ventricle with one of the six MDA-MB-231 cell lines: parental, shNT#3, shHIF#3, DNRII, and DNRII/shNT#2 or DNRII/shHIF#22. Mice were followed by radiography for the development of osteolytic lesions. Lesion area on x-ray was decreased by knockdown of HIF-1alpha (shHIF#3) or blockade of TGF-beta (DNRII or DNRII/shNT#2) (P<0.001 shHIF#3 and DNRII compared to parental and P<0.05 shHIF#3 compared to shNT#3) (Figure 9A-B). Combined inhibition of TGF-beta and HIF-1alpha (DNRII/shHIF#22) had no additional effect on osteolysis. Survival of mice with MDA-MB-231 bone metastases was improved with HIF-1alpha knockdown or TGF-beta blockade (Figure 9C). Combined inhibition of these pathways yielded no further improvement in survival. Quantitative histomorphometry for tumor burden was analyzed as a secondary endpoint for this experiment. There was no difference in tumor burden at time of death in the mice with shHIF, DNRII, or shHIF/DNRII bone metastases compared to the control groups (Figure 9D), which was not unexpected because the survival of these mice was increased.
###end p 46
###begin title 47
###xml 84 92 77 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
HIF-1alpha knockdown and TGF-beta blockade decreases VEGF and CXCR4 mRNA expression in vitro.
###end title 47
###begin p 48
###xml 235 236 226 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 370 371 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 866 867 838 839 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sub>
###xml 1073 1074 1038 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1235 1236 1193 1194 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1344 1345 1300 1301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1355 1356 1311 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1367 1368 1323 1324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 877 880 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(A) MDA-MB-231 dominant-negative TbetaRII expressing cells (DNRII) were transfected with a pLKO.1 vector expressing a non-target shRNA (DNRII/shNT#2 and #4) or an shRNA against HIF-1alpha (DNRII/shHIF#22 and #26) were cultured +/- 1% O2 during 6 h. Total RNA was extracted and mean +/- SEM expression of HIF-1alpha was measured using semi-quantitative RT-PCR (n = 3). * P<0.05 compared to parental (P), using an unpaired Student's t test. (B) Proteins were extracted from treated cells and HIF-1alpha level was assayed by Western-blotting. alpha-tubulin was used as loading control. (C) MDA-MB-231 parental cells (P) and DNRII clones were treated +/- TGF-beta (5 ng/mL) for 2 h. Proteins were extracted and analyzed for phosphorylated Smad2 (pSmad2) and total Smad2 by Western-blotting. (D) MDA-MB-231 parental cells (P) and DNRII clones transfected with pGL3-(CAGA)9 and phRL-CMV plasmids were treated +/- TGF-beta (5 ng/mL) during 24 h before measuring dual-luciferase activity. Results are expressed as the mean +/- SEM of the relative luciferase activity (n = 3). **** P<0.001, using an unpaired Student's t test. (E) Total RNA was extracted from MDA-MB-231 parental (P) and DNRII clones treated +/- TGF-beta (5 ng/mL) and +/- 1% O2 during 24 h. Mean +/- SEM VEGF and CXCR4 expression was measured using semi-quantitative RT-PCR (n = 3). * P<0.05, ** P<0.01, *** P<0.005, using an unpaired Student's t test.
###end p 48
###begin title 49
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Combined HIF-1alpha knockdown and TGF-beta blockade provides no further benefit in mice with bone metastases.
###end title 49
###begin p 50
###xml 394 396 392 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 434 436 427 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 569 571 562 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 627 629 615 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 914 918 900 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N.S.</italic>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 286 290 <span type="species:ncbi:10090">mice</span>
###xml 364 369 <span type="species:ncbi:10090">mouse</span>
###xml 551 556 <span type="species:ncbi:10090">mouse</span>
(A) Representative x-ray images from hindlimbs of mice 4 weeks post inoculation with MDA-MB-231 parental, shNT#3, shHIF#3, DNRII, DNRII/shNT#2 and DNRII/shHIF#22 cells. Arrows indicate osteolytic lesions. (B) Osteolytic lesion area measured on radiographs of hindlimbs and forelimbs of mice with bone metastases. Results are expressed as the mean area +/- SEM per mouse (n = 6-11 per group). * P<0.001 compared to parental and dagger P<0.05 compared to shNT#3 using a two-way ANOVA with a Bonferroni post-test at 3 weeks. (C) Kaplan-Meyer analysis of mouse survival. * P<0.001 shHIF#3 and DNRII compared to Parental and dagger P<0.005 shHIF#3 compared to shNT#3 using a Logrank test. (D) Tumor burden in hindlimbs was measured by quantitative histomorphometry. Results are expressed as the mean +/- SEM area per bone. A one-way ANOVA with a Newman-Keuls multiple comparison test showed no significant differences (N.S.) between groups.
###end p 50
###begin p 51
To determine if the observed effects were bone specific, we analyzed tumor growth following inoculation of these clones into the mammary fat pad. Tumor take and rate of growth were similar for the parental, DNRII, and DNRII/shNT#2 clones, but decreased in the shHIF#3 and DNRII/shHIF#22 clones (data not shown). The data suggest that HIF-1alpha knockdown may decrease bone metastases by inhibiting tumor cell proliferation rather than increasing apoptosis, as TUNEL staining of bone metastases tumor sections demonstrated no difference in tumor cell apoptosis in shHIF compared to parental or shNT bone metastases (data not shown).
###end p 51
###begin title 52
Pharmacologic inhibition of HIF-1alpha with 2ME2 decreases osteolytic lesion area and tumor burden in a preventive model of bone metastasis
###end title 52
###begin p 53
###xml 459 463 448 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Mabjeesh1">[32]</xref>
###xml 464 468 453 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Zhou1">[34]</xref>
###xml 564 572 549 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 574 583 559 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g001">Figure 1A</xref>
###xml 680 684 665 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Cicek1">[42]</xref>
###xml 773 777 758 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Tevaarwerk1">[43]</xref>
###xml 980 989 <span type="species:ncbi:10090">nude mice</span>
The preceding studies provide proof of principle that the HIF-1alpha and TGF-beta signaling pathways in breast cancer cells promote skeletal metastases. Molecular blockade of either pathway prevents tumor growth in bone although the effects were not additive. To determine whether systemic inhibition of these pathways in tumor and host cells provided similar benefit, we used a pharmacologic approach with the HIF-1alpha inhibitor, 2-methoxyestradiol (2ME2) [32]-[34]. We showed that 2ME2 decreases HIF-1alpha protein expression in MDA-MB-231 breast cancer cells in vitro (Figure 1A). 2ME2 was also previously shown to decrease osteolysis in a 4T1 breast cancer metastasis model [42]. Here, we tested a nanocrystalline dispersion formulation with improved bioavailability [43] in a prevention model for breast cancer bone metastases. Drug treatment (150 mg/kg i.p.) was initiated two days prior to the inoculation of tumor cells and continued daily during the experiment. Female nude mice (n = 15 per group) were inoculated into the left cardiac ventricle with MDA-MB-231 cells and the development of osteolytic lesions was followed by radiography. Animals were euthanized at the same time point in order to compare tumor burden between the vehicle and 2ME2 treated groups.
###end p 53
###begin p 54
###xml 70 72 70 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 79 89 79 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g010">Figure 10A</xref>
###xml 165 167 165 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 175 185 175 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g010">Figure 10B</xref>
###xml 376 383 372 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 385 395 381 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g010">Figure 10C</xref>
###xml 482 484 478 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 497 507 493 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g010">Figure 10D</xref>
###xml 270 274 <span type="species:ncbi:10090">mice</span>
###xml 321 325 <span type="species:ncbi:10090">mice</span>
###xml 447 451 <span type="species:ncbi:10090">mice</span>
Preventive treatment with 2ME2 significantly reduced osteolysis area (P<0.01) (Figure 10A) with a consistent decrease in tumor burden by histomorphometric analyses (P<0.005) (Figure 10B). Staining for nuclear HIF-1alpha in the tumor cells was significantly decreased in mice treated with 2ME2 compared to vehicle-treated mice, confirming that the 2ME2 treatment was effective in vivo (Figure 10C). Tumor hypoxia was also decreased in 2ME2-treated mice as demonstrated by HypoxyprobeTM-1 staining (Figure 10D). The data indicate that 2ME2 effectively inhibits HIF-1alpha expression within the tumor microenvironment.
###end p 54
###begin title 55
###xml 84 88 <span type="species:ncbi:10090">mice</span>
Preventive treatment with the HIF-1alpha inhibitor 2ME2 inhibits bone metastases in mice.
###end title 55
###begin p 56
###xml 336 338 332 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1146 1148 1112 1114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 305 310 <span type="species:ncbi:10090">mouse</span>
###xml 773 777 <span type="species:ncbi:10090">mice</span>
###xml 994 999 <span type="species:ncbi:10090">mouse</span>
###xml 1340 1345 <span type="species:ncbi:10090">mouse</span>
(A) Representative 4-week x-rays from mice inoculated with MDA-MB-231 cells and treated +/- 2ME2 (150 mg/kg), arrows indicate osteolytic lesions. Osteolytic lesion area was measured on radiographs of hindlimbs and forelimbs of mice with bone metastases. Results are expressed as the mean +/- SEM area per mouse (n = 10-12 per group). * P<0.01 using a two-way ANOVA with a Bonferroni post-test at 4 weeks. (B) Representative histology of tibias with tumor indicated by arrows. Scale bar equal to 500 microm. Tumor burden in hindlimbs and humeri was measured by quantitative histomorphometry. Results are expressed as the mean +/- SEM area per bone, analysis by unpaired Student's t test. (C) Representative HIF-1alpha staining in demineralized bone metastases sections from mice treated +/- 2ME2. Arrows indicate HIF-1alpha positive nuclei. Scale bar equals 25 microm. The percentage of nuclei positive for HIF-1alpha was calculated in three non-overlapping fields at 400xmagnification for each mouse (n = 6 per group). Results are the mean +/- SEM number of HIF-1alpha positive nuclei per field using an unpaired Student's t test. (D) HypoxyprobeTM-1 staining for tumor hypoxia in bone metastases sections. Hypoxic regions indicated by asterisks. Staining was graded on a 1-4+ scale in three non-overlapping fields at 400xmagnification per mouse (n = 3 per group). Results are the mean +/- SEM staining per field using an unpaired Student's t test.
###end p 56
###begin title 57
2ME2 increases bone mass by increasing osteoblasts and inhibiting osteoclasts in bone unaffected by tumor
###end title 57
###begin p 58
###xml 262 264 262 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 282 284 282 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 313 323 313 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g011">Figure 11A</xref>
###xml 467 477 467 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g011">Figure 11B</xref>
###xml 742 746 742 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&#8202;=&#8202;</italic>
###xml 754 766 754 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g011">Figure 11C&#8211;D</xref>
###xml 808 812 808 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&#8202;=&#8202;</italic>
###xml 820 832 820 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g011">Figure 11E&#8211;F</xref>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 193 197 <span type="species:ncbi:10090">Mice</span>
###xml 461 465 <span type="species:ncbi:10090">mice</span>
###xml 854 858 <span type="species:ncbi:10090">mice</span>
To determine the effects of 2ME2 in normal bone, mice were treated with 2ME2 (150 mg/kg i.p) daily for 4 weeks. Bone mineral density (BMD) was measured weekly by DXA throughout the experiment. Mice treated with 2ME2 had significantly increased BMD at the tibia (P<0.001) and femur (P<0.05), but not at the spine (Figure 11A). Trabecular bone was increased at the distal femur and proximal tibia by 2ME2 treatment, as demonstrated by histology of bones from the mice (Figure 11B). To determine if alterations in bone resorption or bone formation were responsible for the increase bone mass, we counted osteoclast and osteoblast on histologic sections of bone using histomorphometric analysis. Osteoclast number per bone surface was decreased (P = 0.0077, Figure 11C-D), while osteoblast number was increased (P = 0.0002, Figure 11E-F) in the 2ME2-treated mice compared to vehicle-treated controls. The data suggest that 2ME2 may inhibit bone metastases through direct effects on bone by inhibiting osteoclast and increasing osteoblast activity, in addition to its effects on tumor cells.
###end p 58
###begin title 59
2ME2 increases bone density, inhibits osteoclasts and increases osteoblasts in normal bone unaffected by tumor.
###end title 59
###begin p 60
###xml 770 771 756 757 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1179 1180 1159 1160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 502 506 <span type="species:ncbi:10090">mice</span>
###xml 865 869 <span type="species:ncbi:10090">mice</span>
(A) Bone mineral density of the femur, tibia, and spine measured by DXA in mice treated +/- 2ME2 (150 mg/kg). Results are expressed as the mean +/- SEM % change in BMD (n = 10 per group). Statistical analysis by two-way ANOVA with a Bonferroni post-test at week 4. (B) Representative histology of tibias from mice +/- 2ME2 (150 mg/kg) for 4 weeks. Trabecular bone is indicated by arrows. Scale bar equal to 500 microm. (C) Representative TRAP staining of bone histology of the proximal tibias from the mice. TRAP+ osteoclasts (OC) are indicated by arrows. Scale bar is equal to 50 microm. (D) Osteoclast number was measured in the distal femur and proximal tibia at 200xmagnification on TRAP stained slides. Results are expressed as the number of osteoclasts (OC) per mm2 bone surface (BS). (E) Representative H&E stained bone histology of the proximal tibias from mice treated +/- 2ME2 (150 mg/kg). Osteoblasts (OB) indicated by arrows. Scale bar is equal to 50 microm. (F) Osteoblast number was measured below the primary spongiosa in the distal femur and proximal tibia at 200xmagnification on H&E stained slides. Results are expressed as the number of osteoblasts (OB) per mm2 bone surface (BS).
###end p 60
###begin title 61
Pharmacologic inhibition of TbetaRI reduces the development and progression of breast cancer metastases to bone and improves survival
###end title 61
###begin p 62
###xml 475 487 465 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g012">Figure 12A&#8211;B</xref>
###xml 581 593 571 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g012">Figure 12C&#8211;D</xref>
###xml 796 806 786 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g012">Figure 12E</xref>
###xml 213 217 <span type="species:ncbi:10090">Mice</span>
To compare single systemic inhibition of HIF-1alpha with inhibition of TGF-beta signaling, we tested the efficacy of SD-208, a small molecule inhibitor of TbetaRI kinase, in a prevention model of bone metastasis. Mice were treated with either 0.3 or 1.0 mg/mL SD-208 in the drinking water, beginning two days prior to tumor inoculation and continuing for the duration of the study. Both doses of SD-208 significantly reduced the osteolytic lesions detectable on radiography (Figure 12A-B). Histomorphometric analysis of total tumor area showed a similar reduction in tumor burden (Figure 12C-D). Furthermore, SD-208 treatment resulted in a dose-dependent increase in median survival compared to control animals (25, 35 and 37 days for vehicle, 0.3 and 1.0 mg/mL SD-208, respectively, p = 0.008) (Figure 12E).
###end p 62
###begin title 63
Preventive treatment with SD-208 reduces osteolytic bone lesions and increases survival.
###end title 63
###begin p 64
###xml 351 353 347 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 339 344 <span type="species:ncbi:10090">mouse</span>
###xml 834 839 <span type="species:ncbi:10090">mouse</span>
(A) Representative x-ray images from hindlimbs of mice inoculated with MDA-MB-231 cells and treated +/- SD-208 (0.3 mg/mL or 1.0 mg/mL), arrows indicate osteolytic bone lesions. (B) Osteolytic lesion area measured on radiographs of hindlimbs and forelimbs from mice with bone metastases. Results are expressed as the mean area +/- SEM per mouse. **** P<0.0001 0.3 mg/mL and 1.0 mg/mL SD-208 compared to vehicle, using a two-way ANOVA with a Bonferroni post-test at 4 weeks. (C) Representative histology of femurs with tumor indicated by arrows. Scale bar equal to 500 microm. (D) Tumor burden in hindlimbs and humeri was measured by quantitative histomorphometry. Results are expressed as the mean +/- SEM area per bone. Statistical analysis by one-way ANOVA with a Newman-Keuls multiple comparison test. (E) Kaplan-Meyer analysis of mouse survival analyzed using a Logrank test.
###end p 64
###begin title 65
###xml 118 122 <span type="species:ncbi:10090">mice</span>
Combined inhibition of HIF-1alpha and TGF-beta with small molecule inhibitors additively decreases bone metastases in mice
###end title 65
###begin p 66
###xml 129 133 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Ge1">[14]</xref>
###xml 135 139 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Uhl1">[31]</xref>
###xml 970 972 960 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 988 990 978 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1023 1033 1013 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g013">Figure 13A</xref>
###xml 1089 1091 1079 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1100 1102 1090 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1390 1402 1380 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g013">Figure 13B&#8211;C</xref>
###xml 1510 1512 1500 1502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1519 1531 1509 1521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g013">Figure 13B&#8211;C</xref>
###xml 237 241 <span type="species:ncbi:10090">Mice</span>
###xml 495 499 <span type="species:ncbi:10090">Mice</span>
###xml 751 755 <span type="species:ncbi:10090">mice</span>
###xml 1165 1169 <span type="species:ncbi:10090">Mice</span>
###xml 1384 1388 <span type="species:ncbi:10090">mice</span>
Next, we tested whether combined systemic inhibition of HIF-1alpha with 2ME2 and TGF-beta with a TbetaRI kinase inhibitor SD-208 [14], [31] provided additional therapeutic benefit in a therapeutic model of breast cancer bone metastasis. Mice were inoculated with MDA-MB-231 cells and were followed by x-ray for the development of bone metastases. Treatment was initiated when osteolytic lesions were observed on x-ray at 12 days post tumor inoculation and continued daily during the experiment. Mice (n = 15/group) were randomized to one of four treatment groups: vehicle, 2ME2 alone (150 mg/kg i.p.), SD-208 alone (60 mg/kg by oral gavage), or 2ME2 and SD-208 combined. To control for the effects of the different methods of drug administration, all mice received daily i.p. injection with either 2ME2 or PBS vehicle and oral gavage with either SD-208 or 1% methylcellulose vehicle. Treatment with either 2ME2 or SD-208 alone significantly decreased x-ray lesion area (P<0.01 SD-208 and P<0.001 2ME2 compared to vehicle) (Figure 13A), which was further decreased with combined treatment (P<0.01 and P<0.05 SD-208 + 2ME2 compared to SD-208 and 2ME2, respectively). Mice were euthanized at the same time point and histomorphometric analysis showed a corresponding decrease in tumor burden in the femora, tibiae and humeri of 2ME2 and SD-208-treated animals compared to vehicle-treated mice (Figure 13B-C). Tumor burden was further decreased by treatment with SD-208 and 2ME2 combined, compared to SD-208 alone (P<0.05) (Figure 13B-C). A trend towards an additional decrease with combined treatment compared to 2ME2 treatment alone did not reach significance.
###end p 66
###begin title 67
###xml 92 96 <span type="species:ncbi:10090">mice</span>
Combined therapeutic treatment with 2ME2 and SD-208 additively decreases bone metastases in mice.
###end title 67
###begin p 68
###xml 391 393 385 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 412 414 406 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 453 455 442 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 485 487 462 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 835 837 806 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 848 850 819 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1105 1107 1074 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 1118 1120 1087 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
###xml 360 365 <span type="species:ncbi:10090">mouse</span>
(A) Representative x-ray images from hindlimbs of mice inoculated with MDA-MB-231 cells and therapeutically treated +/- 2ME2 (150 mg/kg) and +/- SD-208 (60 mg/kg), arrows indicate osteolytic lesions and osteolytic lesion area measured on radiographs of hindlimbs and forelimbs from mice with bone metastases. Results are expressed as the mean area +/- SEM per mouse (n = 12-14 per group). * P<0.01 SD-208 and ** P<0.001 2ME2 compared to vehicle, dagger P<0.01 SD-208 and double dagger P<0.05 2ME2 compared to SD-208 + 2ME2, using a two-way ANOVA with a Bonferroni post-test at 3 weeks. (B) Representative histology of femurs with tumor indicated by arrows. Scale bar equal to 500 microm. (C) Tumor burden in hindlimbs and humeri was measured by quantitative histomorphometry. Results are expressed as the mean +/- SEM area per bone. * P<0.05, **** P<0.001, using a one-way ANOVA with a Newman-Keuls multiple comparison test. (D) Osteoclast number per mm bone surface (BS) was counted in TRAP stained bone metastases sections. Results are expressed as mean +/- SEM OC number per millimeter BS per bone. ** P<0.01, **** P<0.001, using a one-way ANOVA with a Newman-Keuls multiple comparison test.
###end p 68
###begin p 69
We observed similar effects in a preventive model for breast cancer bone metastasis (data not shown). In this model, treatment with 2ME2 and SD-208 was initiated two days prior to tumor inoculation. Tumor burden was significantly decreased by combined treatment compared to SD-208 alone, with a trend towards an additional decrease compared to 2ME2. Together, these studies suggest that combined pharmacologic targeting of HIF-1alpha and TGF-beta effectively reduces the development and progression of osteolytic bone metastases greater than either alone.
###end p 69
###begin title 70
Combined treatment with 2ME2 and SD-208 decreases osteoclast number at sites of bone metastases
###end title 70
###begin p 71
###xml 561 563 561 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 639 641 639 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P&lt;</italic>
###xml 648 658 648 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006896-g013">Figure 13D</xref>
###xml 392 396 <span type="species:ncbi:10090">mice</span>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
###xml 555 559 <span type="species:ncbi:10090">mice</span>
We hypothesized that combined 2ME2 and SD-208 additionally decrease bone metastases by targeting other cells in the bone metastatic microenvironment in addition to tumor cells. Because breast cancer cells secrete factors which stimulate osteoclast formation and bone resorption in osteolytic metastases, we analyzed osteoclast number at sites of bone metastases from 2ME2- and SD-208-treated mice. Significantly fewer osteoclasts per millimeter of tumor-bone interface were present in bone metastases from 2ME2- or SD-208-treated mice compared to control mice (P<0.01). This number was further reduced with combined 2ME2/SD-208 treatment (P<0.01) (Figure 13D). These results suggest that 2ME2 and SD-208 decrease bone metastases through combined effects to reduce osteoclasts at sites of bone metastases, in addition to their actions on tumor cells.
###end p 71
###begin title 72
Discussion
###end title 72
###begin p 73
###xml 268 271 268 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Roodman1">[1]</xref>
###xml 362 366 362 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Coleman1">[44]</xref>
###xml 368 372 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Lipton1">[45]</xref>
###xml 704 707 701 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Mundy1">[2]</xref>
###xml 727 731 724 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Hiraga1">[46]</xref>
###xml 757 760 751 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Mundy1">[2]</xref>
###xml 889 892 883 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Yin1">[6]</xref>
###xml 894 897 888 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Kakonen1">[7]</xref>
###xml 954 958 945 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Javelaud1">[13]</xref>
###xml 960 964 951 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Ao1">[26]</xref>
###xml 976 980 967 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Duivenvoorden1">[24]</xref>
###xml 982 986 973 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Iida1">[25]</xref>
###xml 1102 1105 1093 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Chiang1">[5]</xref>
###xml 1189 1192 1180 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Kang1">[8]</xref>
###xml 1194 1201 1185 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006896-t001">Table 1</xref>
###xml 1246 1250 1237 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Hirao1">[19]</xref>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Bone metastases occur in eighty percent of patients with advanced breast cancer. They are incurable and cause significant morbidity, including pain, pathologic fractures, hypercalcemia, and nerve compression syndromes due to tumor-induced osteoclastic bone resorption [1]. Standard bisphosphonate therapies improve skeletal morbidity by reducing this osteolysis [44], [45], but do not cause regression of established bone metastases. The bone microenvironment by its unique composition of growth factors housed in the mineralized bone matrix, bone resorbing and bone forming cells, promotes a feed-forward cycle of site-specific metastasis through high concentrations of growth factors, such as TGF-beta [2], and local hypoxia [46]. Active TGF-beta in bone [2] promotes bone metastases by increasing tumor production of factors that stimulate osteoclastic bone resorption and tumor growth [6], [7]. TGF-beta-regulated factors, such as CTGF, IL-11, CXCR4 [13], [26], and MMP-1 [24], [25] are involved in multiple steps of the metastatic cascade, including invasion, homing, angiogenesis, and osteolysis [5] and constitute a gene signature for tumors that metastasize preferentially to bone [8] (Table 1). The bone microenvironment is also hypoxic [19]. Hypoxia activates signaling through HIF-1alpha which, like TGF-beta, increases many of the factors that promote the feed-forward metastatic cycle. Although previous studies have shown that both HIF-1alpha and TGF-beta signaling pathways are important in bone metastases, interactions between these factors have not been reported. The aim of these studies was to determine whether TGFbeta and hypoxia act synergistically or work redundantly to promote bone metastases.
###end p 73
###begin p 74
###xml 56 64 56 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 169 170 166 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 355 356 346 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 625 633 606 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 633 637 614 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Jeon1">[47]</xref>
###xml 820 824 798 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-SanchezElsner1">[48]</xref>
###xml 954 958 929 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Jeon1">[47]</xref>
###xml 482 487 <span type="species:ncbi:10090">mouse</span>
###xml 739 744 <span type="species:ncbi:10090">mouse</span>
###xml 800 805 <span type="species:ncbi:9606">human</span>
###xml 1042 1047 <span type="species:ncbi:9606">human</span>
###xml 1129 1134 <span type="species:ncbi:9606">human</span>
We first investigated interactions between the pathways in vitro by analyzing changes in gene expression in MDA-MB-231 breast cancer cells treated with TGF-beta and 1% O2. Of 16 candidate genes, only two were increased by TGF-beta and hypoxia: VEGF and CXCR4. VEGF, but not CXCR4, mRNA was additively increased by combined treatment with TGF-beta and 1% O2, and promoter activation of the two factors was also additively increased by combined treatment. Previous studies of VEGF in mouse macrophages showed increased promoter activity in response to TGF-beta and hypoxia and to overexpression of HIF-1alpha/beta and Smads3/4 in vitro[47]. Elements responsible for TGF-beta and hypoxia response were localized in the proximal region of the mouse VEGF promoter and homolog sites were identified in the human VEGF promoter [48]. The study demonstrated that TGF-beta and hypoxia signaling directly crosstalk to regulate the expression of VEGF in macrophages [47]. The data here suggest that VEGF is regulated similarly by TGF-beta and hypoxia in human MDA-MB-231 cells. An HRE located 1.3 kb from the transcription start site in the human CXCR4 promoter was found to mediate its response to hypoxia. Mutation of either of two putative SBEs did not significantly inhibit TGF-beta-stimulated CXCR4 promoter activation. The results suggest that TGF-beta regulates CXCR4 through other SBEs in the promoter that were not tested here.
###end p 74
###begin p 75
###xml 363 370 353 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 672 679 655 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1395 1399 1366 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Hiraga1">[46]</xref>
###xml 1461 1469 1428 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1595 1601 1562 1568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1767 1771 1730 1734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Liao1">[49]</xref>
###xml 667 671 <span type="species:ncbi:10090">mice</span>
###xml 794 798 <span type="species:ncbi:10090">mice</span>
###xml 886 890 <span type="species:ncbi:10090">mice</span>
###xml 1297 1301 <span type="species:ncbi:10090">mice</span>
###xml 1682 1697 <span type="species:ncbi:10090">transgenic mice</span>
MDA-MB-231 cells did not show significant additive responses to TGF-beta and hypoxia for the other 14 genes examined, but other targets could be responsive. Therefore we used a comprehensive approach to genetically approach to inhibit the pathways in the tumor cells by expression of HIF-1alpha shRNA and a dominant-negative TbetaRII, which then were analyzed an in vivo bone metastasis model. This approach permits assessment of the tumor autonomous effects of hypoxia and TGF-beta, separate from their roles in the metastatic microenvironment. Knockdown of HIF-1alpha mRNA in MDA-MB-231 breast cancer cells decreased osteolytic lesion area and improved survival of mice in vivo. Knockdown of HIF-1alpha did not yield a corresponding decrease in tumor burden at time of death. Tumor burden in mice euthanized at the same time point could not be compared in this survival experiment as mice bearing shHIF bone metastases lived significantly longer than the control groups. It is possible that knockdown of HIF-1alpha decreases osteolytic lesion development without affecting the rate of tumor growth in bone. However, this is unlikely as previous studies demonstrated that inhibition of hypoxic signaling by a dominant-negative HIF-1alpha decreased osteolytic bone destruction and tumor burden in mice euthanized at the same time point, while a constitutively active HIF had the opposite effect [46]. Knockdown of HIF-1alpha had no effect on cell proliferation in vitro, but it decreased primary tumor take and growth in the mammary fat pad in our experiments. Consistent with our results, Liao et al. reported that conditional deletion of HIF-1alpha from the mammary epithelium in transgenic mice delayed onset of spontaneous breast tumors and retarded their growth [49].
###end p 75
###begin p 76
###xml 14 22 14 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 170 174 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Wang1">[50]</xref>
###xml 282 290 274 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 321 328 313 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 550 554 538 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Pulaski1">[51]</xref>
###xml 656 660 644 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Cabioglu1">[52]</xref>
###xml 776 780 764 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Richert1">[53]</xref>
###xml 782 786 770 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Tamamura1">[54]</xref>
###xml 849 853 837 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Diamond1">[55]</xref>
###xml 590 595 <span type="species:ncbi:9606">human</span>
###xml 857 861 <span type="species:ncbi:10090">mice</span>
Together, our in vitro and in vivo results suggest that HIF-1alpha promotes bone metastases by regulating factors such as CXCR4, which promotes tumor cell homing to bone [50] and VEGF, which promotes angiogenesis. HIF-1alpha knockdown in MDA-MB-231 cells decreased CXCR4 expression in vitro and inhibited bone metastasis in vivo, with no difference in metastasis to other organs, such as the lungs or adrenal glands. The results suggest that HIF-1alpha knockdown may specifically inhibit skeletal metastases by blocking CXCR4-mediated homing to bone [51]. CXCR4 is more highly expressed in human breast cancer metastases to bone than to the lungs or brain [52]. Previous studies showed that treatment with CXCR4 antagonists inhibited breast cancer metastasis to bone and lung [53], [54] and decreased bone destruction due to myeloma bone metastases [55] in mice, which supports our results.
###end p 76
###begin p 77
###xml 243 251 235 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 314 321 306 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 850 854 838 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Bauerle1">[56]</xref>
###xml 856 860 844 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Bauerle2">[57]</xref>
###xml 710 714 <span type="species:ncbi:10090">mice</span>
###xml 845 849 <span type="species:ncbi:10116">rats</span>
In addition, our results suggest a role for HIF-1alpha to regulate interactions between tumor cells and other cells in the bone microenvironment, such as endothelial cells. Knockdown of HIF-1alpha in MDA-MB-231 cells decreased VEGF expression in vitro, and inhibited tumor angiogenesis at sites of bone metastasis in vivo, as demonstrated by CD31 staining for endothelial cells. There was no difference in the number of vessels in shHIF mammary fat pad tumors compared to parental and shNT control tumors (data not shown). The results suggest that knockdown of HIF-1alpha specifically inhibits vessel formation within the hypoxic bone microenvironment, which may contribute to decreased bone metastasis in the mice. Consistent with this, treatment with a VEGF neutralizing antibody decreased tumor angiogenesis and osteolytic bone metastases in rats [56], [57].
###end p 77
###begin p 78
###xml 138 141 128 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Yin1">[6]</xref>
###xml 556 564 546 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 201 205 <span type="species:ncbi:10090">mice</span>
Inhibition of either HIF-1alpha or TGF-beta signaling in the tumor cells by shRNA knockdown or expression of a dominant-negative TbetaRII [6] decreased osteolytic lesion area and increased survival of mice with bone metastases compared to those bearing control cells. However, there was no additional survival benefit or reduction in lesion area with combined inhibition of these pathways. The results suggest that the two signaling pathways function in parallel and independently of one another in tumor cells. This conclusion is supported by the results in vitro where HIF-1alpha and TGF-beta regulated many of the same prometastatic factors independently, with few additive responses.
###end p 78
###begin p 79
###xml 490 494 483 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Mabjeesh1">[32]</xref>
###xml 496 500 489 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Mooberry1">[58]</xref>
###xml 502 506 495 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Mooberry2">[59]</xref>
###xml 590 594 583 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Cicek1">[42]</xref>
###xml 693 701 682 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 827 831 816 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Mabjeesh1">[32]</xref>
###xml 1067 1071 1052 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Cicek1">[42]</xref>
###xml 1240 1247 1221 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 559 564 <span type="species:ncbi:10090">mouse</span>
Genetic inhibition tests the role of tumor cell HIF-1alpha and TGF-beta signaling in bone metastasis but fails to address contributions from the microenvironment. In addition, shRNA knockdowns and dominant-negative receptors are not readily translatable to the clinic. Therefore we used small molecule inhibitors to inhibit these pathways systemically. 2ME2 is a naturally occurring, poorly-estrogenic metabolite of estradiol with anti-HIF, anti-angiogenic, and anti-microtubule properties [32], [58], [59]. The drug decreased osteolytic lesion area in a 4T1 mouse model of bone metastasis [42]. In our studies a soluble formulation of 2ME2 effectively inhibited HIF-1alpha protein expression in vitro for three bone metastatic cell lines: MDA-MB-231 breast, PC-3 prostate and 1205Lu melanoma cells, as demonstrated previously [32]. Systemic inhibition of HIF-1alpha by 2ME2 significantly decreased osteolytic lesion area and reduced tumor burden in a prevention model of MDA-MB-231 breast cancer bone metastasis, consistent with the previous studies using 4T1 cells [42]. Staining for HIF-1alpha and tumor hypoxia were decreased in bone metastases sections from 2ME2-treated animals, demonstrating on-target effects of 2ME2 in tumor cells in vivo.
###end p 79
###begin p 80
###xml 296 300 293 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Uhl1">[31]</xref>
###xml 426 430 417 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Bandyopadhyay1">[15]</xref>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 421 425 <span type="species:ncbi:10090">mice</span>
Similarly, we showed that a TbetaRI kinase inhibitor, SD-208, significantly reduced osteolytic lesion area and decreased tumor burden in mice, while increasing survival in a dose dependent manner. SD-208 was previously shown to increase survival following orthotopic implantation of glioma cells [31]. Inhibition of TGF-beta by another TbetaRI kinase inhibitor decreased breast cancer metastases to lungs and skeleton in mice [15].
###end p 80
###begin p 81
Combined treatment with 2ME2 and SD-208 significantly decreased osteolytic lesion area on x-ray and reduced tumor burden by quantitative histomorphometry compared to vehicle or either drug alone in a clinically relevant therapeutic, as well as a prevention model of bone metastasis. Unlike the previous genetic studies where inhibition of HIF-1alpha and TGF-beta in tumor cells had no additional effect, combined pharmacologic inhibition of these pathways with 2ME2 and SD-208 provided added therapeutic benefit, which may be due actions of the drugs on tumor cells and other cells in the bone microenvironment, such as osteoclasts. In the bone metastasis model, treatment with 2ME2 or SD-208 alone decreased the number of osteoclasts at the tumor-bone interface, which was further reduced with combined treatment. These data, together with the additive effect of 2ME2 and SD-208 on radiographic bone destruction induced by MDA-MB-231 cells, suggest that these drugs may prevent tumor-induced bone destruction by inhibiting osteoclast formation.
###end p 81
###begin p 82
###xml 264 268 261 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Mohammad1">[60]</xref>
###xml 633 637 618 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Wang2">[61]</xref>
###xml 802 806 779 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Komatsu1">[62]</xref>
###xml 995 999 964 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Arnett1">[63]</xref>
###xml 1001 1005 970 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Bozec1">[64]</xref>
###xml 1114 1118 1083 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Knowles1">[65]</xref>
###xml 1120 1124 1089 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Knowles2">[66]</xref>
###xml 1332 1336 1297 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Cicek1">[42]</xref>
###xml 1581 1585 1546 1550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Guise1">[67]</xref>
###xml 1690 1694 1655 1659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Mohammad1">[60]</xref>
###xml 1696 1700 1661 1665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Sibonga1">[68]</xref>
###xml 506 510 <span type="species:ncbi:10090">Mice</span>
###xml 685 689 <span type="species:ncbi:10090">mice</span>
Systemic TGF-beta blockade with SD-208 was previously shown to have profound effects on normal bone remodeling to increase bone mass in part by inhibiting osteoclast formation and bone resorption, as well as to stimulate osteoblast activity and new bone formation [60]. Here we show that 2ME2 also has direct effects on bone to increase bone mass by decreasing osteoclasts and increasing osteoblasts. 2ME2 is an inhibitor of HIF-1alpha, but the effects of HIF-1alpha in bone have been shown to be complex. Mice with a conditional deletion of HIF-1alpha in osteoblasts had smaller, less vascularized bones with decreased bone density [61]. In contrast, partial HIF-1alpha deficiency in mice heterozygous for HIF-1alpha prevented osteoblast apoptosis and enhanced bone mineralization and fracture repair [62]. Our results are consistent with the latter study in that 2ME2 inhibits HIF-1alpha but increases bone mass. In addition, HIF-1alpha also regulates osteoclast formation and bone resorption [63], [64] by increasing VEGF expression which substitutes for M-CSF to promote osteoclastogenesis together with RANKL [65], [66]. 2ME2 may therefore inhibit osteoclast formation and activity indirectly by blocking HIF-1alpha activity and VEGF secretion by osteoblasts. 2ME2 has also been shown to induce apoptosis in mature osteoclasts [42], and may have other effects in bone, as we show here. Importantly, we observed no deleterious effects of these drug treatments on the bones of animals. Unlike most current cancer therapies, including aromatase inhibitors, which cause bone loss [67], 2ME2 and SD-208 have bone-sparing effects that may contribute the beneficial effect on bone metastases [60], [68].
###end p 82
###begin p 83
###xml 155 159 152 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Wang1">[50]</xref>
###xml 236 240 233 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Knowles1">[65]</xref>
###xml 242 246 239 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Zhang1">[69]</xref>
###xml 271 275 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Wang2">[61]</xref>
###xml 784 792 <span type="species:ncbi:9606">patients</span>
Our data establish that hypoxia and TGF-beta signaling pathways regulate tumor-secreted factors such as CXCR4 which promotes tumor cell homing to the bone [50], and VEGF which stimulates tumor angiogenesis and increases both osteoclast [65], [69] and osteoblast activity [61]. Genetic inhibition of either HIF-1alpha or TGF-beta in tumor cells provides proof of principle that these signaling pathways promote bone metastasis through tumor-autonomous effects. Systemic inhibition with 2ME2 or SD-208 also decreased bone metastases, while combined treatment provided additional benefit through effects on the tumor cells, as well as the bone microenvironment. Thus, combination therapy with inhibitors of hypoxia and TGF-beta may significantly improve treatment and impact survival of patients with bone metastases, and provide a welcome addition to current armamentarium for bone metastases.
###end p 83
###begin title 84
Materials and Methods
###end title 84
###begin title 85
Ethics statement
###end title 85
###begin p 86
###xml 304 313 <span type="species:ncbi:10090">nude mice</span>
###xml 421 426 <span type="species:ncbi:10090">mouse</span>
###xml 474 479 <span type="species:ncbi:9606">human</span>
Animal protocols were approved by the Institution Animal Care and Use Committee at the University of Virginia and were in accordance with guidelines from the U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals and in compliance with the U.S. Animal Welfare Act. Female athymic nude mice, 4 weeks of age, were housed under barrier conditions in laminar flow isolated hoods. Autoclaved water and mouse chow were provided ad libitum. Animals bearing human tumor xenografts were carefully monitored for established signs of distress and discomfort and were humanely euthanized when these were confirmed.
###end p 86
###begin title 87
Materials
###end title 87
###begin p 88
###xml 210 214 207 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Tevaarwerk1">[43]</xref>
###xml 344 346 338 340 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 437 441 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Uhl1">[31]</xref>
###xml 12 17 <span type="species:ncbi:9606">human</span>
Recombinant human TGF-beta1 was purchased from R&D Systems (Minneapolis, MN). 2-methoxyestradiol (2ME2) was a gift from Entremed (Rockville, MD) and was provided as an orally-active, nanocrystalline dispersion [43]. SD-208 was obtained from Scios, Inc. (Fremont, CA) and Epichem (Murdoch, Australia). SD-208 is a potent inhibitor of TbetaRI (EC50 = 48 nM) whose selectivity profile for a variety of kinases has been previously described [31]. The drug was resuspended in 1% methylcellulose and stored at 4degreesC.
###end p 88
###begin title 89
Cell lines
###end title 89
###begin p 90
###xml 31 34 31 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Yin1">[6]</xref>
###xml 577 581 577 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Javelaud1">[13]</xref>
###xml 762 763 756 757 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 968 969 962 963 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 976 977 970 971 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 983 984 977 978 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 165 171 <span type="species:ncbi:9913">bovine</span>
MDA-MB-231 breast cancer cells [6] were cultured in Dulbecco's modified Eagle's media (DMEM) (Hyclone Laboratories, Logan, UT) containing 10% heat-inactivated fetal bovine serum (FBS) (Hyclone). HepG2 hepatocarcinoma cells (HB-8065, ATCC, Manassas, VA) were cultured in modified Eagle's media (MEM) supplemented with 10% FBS, sodium pyruvate and non-essential amino acids. PC-3 prostate cancer cells (CRL-1435, ATCC) were cultured in RPMI with 10% FBS. 1205Lu melanoma cells were from Dr. Alain Mauviel, Institut National de la Sante et de la Recherche Medicale, Paris, France [13]. The cells were grown in a composite medium (W489) consisting of three parts of MCDB153 and one part of L15 supplemented with 4% FBS. Cells were maintained at 37degreesC with 5% CO2 in a humidified chamber. Hypoxia treatments were performed by placing tissue culture flasks in a modular incubator chamber (model MC-101, Billups-Rothenberg Inc., Del Mar, CA), flushed with premixed 94% N2, 5% CO2, 1% O2 and maintained in a conventional tissue culture incubator.
###end p 90
###begin title 91
Preparation of stable clones
###end title 91
###begin p 92
Parental MDA-MB-231 cells were transfected with a pLKO.1 plasmid coding an shRNA against HIF-1alpha (TRCNo. TRCN0000003810, MISSION(R) shRNA, Sigma, St. Louis, MO) using FuGENE HD (Roche, Nutley, NJ). Cells transfected with a non-target shRNA control vector (SHC002, MISSION(R) shRNA, Sigma) were used as a control. Single clones were selected by limiting dilution in the presence of puromycin (Invitrogen, San Diego, CA). Knockdown of HIF-1alpha mRNA and protein were confirmed by semi-quantitative RT-PCR and Western blot analysis. Clones were retested for stability (>80% knockdown) after culture in the absence of puromycin for 60 days. Two non-target controls (shNT) and two HIF-1alpha knockdown (shHIF) clones were selected for further study.
###end p 92
###begin p 93
###xml 127 130 117 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Yin1">[6]</xref>
###xml 623 630 602 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 635 643 614 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
The MDA-MB-231 clonal line, MDA/TbetaRIIDeltacyt, which stably expresses a cytoplasmically truncated type II TGF-beta receptor [6], here referred to as dominant-negative receptor II (DNRII), was transfected to express either non-target or HIF-1alpha shRNA. Single cell clones were isolated, selected for resistance to G418 (Alexis Biochemicals, San Diego, CA) and puromycin, and tested for stable knockdown of HIF-1alpha as described previously. Stable DNRII expression and blockade of TGF-beta signaling were confirmed by Western blot for phosphorylated Smad2. Two DNRII/ shNT and two DNRII/shHIF clones were selected for in vivo and in vitro experiments.
###end p 93
###begin title 94
MTT assay
###end title 94
###begin p 95
Cell proliferation was assayed by MTT assay. Cells were plated at a density of 1000 cells/well in 96-well plates. MTT reagent (20 microl, 5 mg/ml) (Calbiochem, San Diego, CA) was added to each well. After a 5 h-incubation at 37degreesC, 100 microL of 0.01M HCL containing 10% SDS were added to lyse the cells and the plate was incubated at 37degreesC for an additional 16 h. Absorbance was measured at 570 nm using a Synergytrade mark HT spectrophotometer (Bio-tek, Winooski, VT).
###end p 95
###begin title 96
Semi-quantitative RT-PCR
###end title 96
###begin p 97
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 221 222 216 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1417 1425 1365 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006896.s001">Table S1</xref>
MDA-MB-231 cells were seeded in 24-well plates (105 cells/well). Forty-eight hours later, cells were starved overnight in basal DMEM media, then treated +/- TGF-beta1 (5 ng/mL) in DMEM-FBS (1%) and cultured in 20% or 1% O2 for 24 h. Cells were rinsed in PBS and then lysed in Trizol (Invitrogen) for RNA extraction. Briefly, chloroform was added to cell lysates. Samples were centrifuged (12,000 g, 15 min, 4degreesC) and the upper aqueous phase was collected. One volume of 70% ethanol was added, then sample was loaded on an RNeasy mini spin column (Qiagen, Valencia, CA) and total RNA was isolated according to manufacturer's instructions. DNase I treatment was performed to remove genomic DNA contamination, and RNA integrity was assessed on agarose gels. RNA (500 ng per sample) was reverse transcribed using Superscript II (Invitrogen) according to the manufacturer's instructions with anchored oligo(dT) (Abgene, Rochester, NY) for priming. The resulting cDNAs were prepared for semi-quantitative real-time PCR using QuantiTect SYBR Green PCR Kit (Qiagen) and analyzed in a MyiQtrade mark Single-Color Real-Time PCR Detection System (BioRad, Hercules, CA) for 40 cycles (95degreesC for 1 min, 58degreesC or 60degreesC for 30 s, 72degreesC for 30 s) after an initial 15-min incubation at 95degreesC. Primers were optimized for real-time PCR (amplification efficiency 100 +/- 5%). Primer sequences are listed in Table S1. Target gene expression was normalized against the housekeeping gene for the ribosomal protein L32, and data were analyzed using the DeltaDeltaCt method.
###end p 97
###begin title 98
Western blot analysis
###end title 98
###begin p 99
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 253 254 253 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1239 1244 <span type="species:ncbi:10090">mouse</span>
###xml 1273 1279 <span type="species:ncbi:9986">rabbit</span>
MDA-MB-231 cells were plated in 12-well plates (2x105 cells/well). Forty-eight hours later, cells were serum starved overnight in basal DMEM, then cultured in DMEM-FBS (1%) for duration of treatment. Hypoxia treatments were performed by culturing in 1%O2 for 6 h. TGF-beta1 (5 ng/mL) treatment was for 2 h. Cells were washed once with PBS, lysed in 200 microl SDS-loading buffer, and heated to 95degreesC for 5 min. Samples were loaded onto a 10% polyacrylamide gel and electrophoresis was performed using a Mini Trans-Blot(R) cell (BioRad, Hercules, CA). Proteins were transferred onto a Hybondtrade mark-P membrane (GE Healthcare, Waukesha, WI) using a Mini-PROTEAN(R) Cell transfer system (BioRad). Membranes were blocked in TBS-T-5% milk for 1 h, incubated overnight with the primary antibody and for 1 h with the secondary antibody. Antibody detection was performed using Immobilontrade mark Western Chemiluminescent HRP Substrate (Millipore, Billerica, MA) according to the manufacturer's directions and signal was visualized on radiographic film. Antibodies used include HIF-1alpha (BD Biosciences, San Jose, CA), phospho-Smad2 (Ser465/467) and Smad2 (Cell Signaling, Danvers, MA); alpha-tubulin (Sigma) was used as a control. Anti-mouse IgG (Fab specific) and anti-rabbit IgG secondary antibodies conjugated to peroxidase were purchased from Sigma.
###end p 99
###begin title 100
Dual-luciferase assays
###end title 100
###begin p 101
###xml 83 84 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sub>
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Bartholin1">[70]</xref>
###xml 136 137 136 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sub>
###xml 278 282 278 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Caruz1">[40]</xref>
###xml 284 288 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Phillips1">[41]</xref>
###xml 396 400 396 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Akagi1">[39]</xref>
###xml 660 661 657 658 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 204 209 <span type="species:ncbi:9606">human</span>
###xml 305 310 <span type="species:ncbi:9606">human</span>
Cells were transfected with pGL3-luciferase constructs containing either the (CAGA)9[70], VEGF or CXCR4 promoter using FuGENE HD. (CAGA)9 contains nine tandemly-repeated Smad binding elements. The 2.6 kb human CXCR4 promoter was from Dr. Robert Strieter, University of Virginia [40], [41], and the 3.3 kb human VEGF promoter was from Dr. Lee Ellis, University of Texas, MD Anderson Cancer Center [39]. Cells were also transfected with a phRL-renilla plasmid (Promega, Madison, WI) for normalization. Twenty-four hours later, cells were cultured serum-starved in basal DMEM medium for 4 h, then treated in the presence or absence of TGF-beta1 (5 ng/mL) and 1% O2 for 24 h. Cells were washed once with PBS, lysed using Passive Lysis Buffer (Promega), and analyzed for luciferase activity using the Dual-Luciferase Reporter Assay System (Promega), according to the manufacturer's instructions on a FB12 Sirius luminometer (Berthold Detection Systems, Oak Ridge, TN).
###end p 101
###begin title 102
Plasmids
###end title 102
###begin p 103
###xml 364 372 360 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006896.s002">Table S2</xref>
###xml 391 417 387 413 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTTCCATCTTCCAGCGGATA-3&#8242;</named-content>
pCEP4-HIF-1alpha (MBA-2) was purchased from the ATCC; pCMV-Smad2 and -Smad3 were from Dr. David Wotton (University of Virginia); pCMV-Smad4 was from Dr. Rik Derynk (University of California San Francisco). VEGF and CXCR4 promoter deletion mutants were generated using forward primers containing a 5' KpnI restriction site and 3' end complementary to the promoter (Table S2). Reverse primer (5'-GTTCCATCTTCCAGCGGATA-3') binds a region of the luciferase coding sequence. Promoter fragments were amplified by PCR using PfuUltratrade mark Hotstart DNA polymerase (Stratagene, La Jolla, CA). Products were digested overnight with KpnI and XhoI, purified on agarose gel (QIAquick Gel Extraction kit, Qiagen), and ligated into the pGL3-luciferase vector using T4 DNA ligase (Roche) according to the manufacturer's instructions. QuikChange(R) II Site-Directed Mutagenesis kit (Stratagene) was used to mutate putative Smad-binding (SBE) and hypoxia response (HRE) elements in the VEGF and CXCR4 promoters. Primers were designed using the QuikChange(R) Primer Design Program (Stratagene) and mutagenesis performed according to the manufacturer's protocol.
###end p 103
###begin title 104
VEGF enzyme-linked immunosorbant assays
###end title 104
###begin p 105
###xml 72 73 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 206 207 199 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
MDA-MB-231 parental cells and clones were plated in 12-well plates (2x105 cells/well) and grown for 48 h. After 4 h serum starvation, cells were treated +/- TGF-beta1 (5 ng/mL) in DMEM-FBS (1%) and +/- 1% O2 for 24 h. Conditioned media was collected and analyzed by ELISA assay for VEGF-A (Bender MedSystems, Inc., Burlingame, CA), according to the manufacturer's instructions. Cell number per well was used for normalization.
###end p 105
###begin title 106
Flow cytometry
###end title 106
###begin p 107
###xml 85 86 85 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 166 167 166 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 321 327 <span type="species:ncbi:9913">bovine</span>
MDA-MB-231 parental cells and clones were plated in triplicate in 6-well plates (5x105 cells/well). Forty-eight hours later, cells were trypsinized, counted, and 5x105 cells per sample were transferred to 5 mL tubes. Cells were centrifuged (1,000 rpm, 5 min, 4degreesC), washed twice with flow cytometry buffer (FCB) (2% bovine serum albumin and 0.2% sodium azide in PBS 1X) and incubated with phycoerythrin-conjugated CXCR4 antibody (eBiosciences, San Diego, CA) for 30 min. Cells were washed twice, fixed in paraformaldehyde (2% in PBS 1X, 15 min, RT) and resuspended in FCB. A FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ) was used for flow cytometry, followed by analysis with FloJo software (TreeStar, Ashland OR).
###end p 107
###begin title 108
In vivo protocols
###end title 108
###begin title 109
Bone metastasis model
###end title 109
###begin p 110
###xml 78 82 78 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Guise2">[71]</xref>
###xml 180 181 180 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
Intracardiac inoculation of tumor cells was performed as previously described [71]. Tumor cells were trypsinized, washed twice and resuspended in PBS to a final concentration of 105 cells in 100 microl. Animals were anesthetized with ketamine/xylazine and positioned ventral side up. MDA-MB-231 parental or clonally-derived cells (n = 12-15) were inoculated into the left ventricle by percutaneous injection using a 26-gauge needle.
###end p 110
###begin title 111
Mammary fat pad tumor model
###end title 111
###begin p 112
###xml 153 154 153 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 448 449 443 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</italic>
###xml 453 454 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">w</italic>
###xml 457 458 452 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 466 467 461 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</italic>
###xml 472 473 467 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">w</italic>
###xml 21 30 <span type="species:ncbi:10090">nude mice</span>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
Four week old female nude mice were anaesthetized with ketamine/xylazine and placed in supine position. MDA-MB-231 parental or clonally-derived cells (106 cells in 100 microL PBS; n = 10 mice per cell line) were inoculated into the upper mammary fat pad using a 27-gauge needle. Tumor size was followed by measuring tumor diameters with calipers three times per week and tumor volume was calculated by the formula of an ovoid: tumor volume = 4/3pixL/2 (w/2)2, where L and w equal mid-axis length and width, respectively.
###end p 112
###begin title 113
Drug treatments
###end title 113
###begin p 114
2ME2 (150 mg/kg) or its vehicle PBS was administered daily by i.p. injection. In the first experiment, SD-208 was administered preventively via the drinking water (either 0.3 or 1 mg/mL) beginning two days prior to tumor inoculation. Vehicle control animals were given water without compound. In all subsequent experiments, SD-208 (60 mg/kg) or its vehicle 1% methylcellulose was administered daily by oral gavage. In the preventive protocols, drug treatment was initiated two days prior to tumor cell inoculation and continued daily for the duration of the study. In the therapeutic protocol, drug treatment was initiated when osteolysis was observed on x-ray and then continued during the duration of the study.
###end p 114
###begin title 115
Radiography
###end title 115
###begin p 116
###xml 135 139 <span type="species:ncbi:10090">Mice</span>
Osteolytic lesions were analyzed by radiography using a Faxitron MX-20 with digital camera (Faxitron X-ray Corporation, Wheeling, IL). Mice were imaged in a prone position at 1xmagnification and 4x when osteolytic lesions were suspected. Osteolytic lesion area was quantified using MetaMorph software (Universal Imaging Corporation, Dowingtown, PA).
###end p 116
###begin title 117
Bone mineral density (BMD) measurement
###end title 117
###begin p 118
###xml 678 679 678 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 26 30 <span type="species:ncbi:10090">mice</span>
###xml 75 80 <span type="species:ncbi:10090">mouse</span>
###xml 249 255 <span type="species:ncbi:10090">murine</span>
###xml 276 280 <span type="species:ncbi:10090">Mice</span>
BMD was performed on live mice using a GE Lunar PIXImus II (GE Healthcare) mouse densitometer (Faxitron X-ray Corporation). Measurements were performed one time/week throughout the experiment. The densitometer was calibrated with a plastic embedded murine phantom before use. Mice were anesthetized, placed on an adhesive tray in a prone position with limbs spread. Total body measurement was performed excluding the calvarium, mandible and teeth. A region of interest was defined at the distal femur, proximal tibia just beneath the growth plate (12x12 pixels) and the lower lumber spine (20x50 pixels). Values were expressed as percentage change in BMD over base line in mg/cm2.
###end p 118
###begin title 119
Bone histology & histomorphometry
###end title 119
###begin p 120
###xml 1128 1132 1124 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006896-Yin2">[72]</xref>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
Forelimbs, hindlimbs, and spine of the mice were collected upon euthanasia and fixed in 10% neutral buffered formalin for 48 h and decalcified in 10% EDTA for 2 weeks. After decalcification tissues were processed in a Shandon Excelsior automated tissue processor (Thermo Fisher Scientific, Waltham, MA) and embedded in paraffin wax for sectioning. Longitudinal, mid-sagittal sections 3.5 microm in thickness from the tibia, femur and lumbar spines were cut using an automated Microm HM 355 S microtome (Thermo Fisher Scientific). Tissue sections were stained with hematoxylin and eosin (H&E) and prepared for histomorphometric analysis. All sections were viewed on a Leica DM LB compound microscope (Leica Microsystems, Bannockburn, IL) with a Q-Imaging Micropublisher Cooled CCD color digital camera (Vashaw Scientific Inc., Washington, DC). Images were captured and analyzed using MetaMorph software (Universal Imaging Corporation). Tumor burden per bone, defined as area of bone occupied by the cancer cells, was calculated at the tibia, femur and humerus at 50xmagnification on H&E stained sections, as previously described [72]. Osteoclast number at the tumor-bone interface (OC/mm bone surface) in the femur, tibia and humerus was measured on TRAP stained slides at 200xmagnification. For normal bone, osteoblast (OB) number and osteoclast (OCL) number at the bone surface were measured in the distal femur and proximal tibia at 200xmagnification on H&E and TRAP stained slides, respectively.
###end p 120
###begin title 121
###xml 11 14 11 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> TM</sup>
Hypoxyprobe TM-1 staining for tumor hypoxia
###end title 121
###begin p 122
###xml 147 149 147 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
For assessment of tumor hypoxia, mice were injected 2 h prior to euthanasia with pimonidazole (60 mg/kg i.p.) and sections stained with HypoxyprobeTM-1 kit (Natural Pharmacia International, Inc., Burlington, MA) according to the manufacturer's instructions. Tumor hypoxia in bone metastases tumor sections was scored semi-quantitatively on a 1-4 + scale, based on the percentage of positively stained tumor within a 400x field: grade 1: 25% staining, 2: 50%, 3: 75%, and 4: 100%.
###end p 122
###begin title 123
Immunohistochemistry
###end title 123
###begin p 124
Immunohistochemical analysis was performed on decalcified paraffin-embedded tissue sections. Antibodies against HIF-1alpha and CD31 were purchased from BD Biosciences. All staining was performed using VECTASTAIN(R) Elite ABC kit (Vector Laboratories, Burlingame, CA). Slides were stained using a 3,3, diaminobenzidine substrate kit (Vector Laboratories) and counterstained with hematoxylin. HIF-1alpha and CD31 staining were quantified by the percentage of positively staining nuclei per 400x field and number of vessels per 200x field, respectively. Three or more fields per animal were analyzed and averaged. Averages for 3 or more animals per group were compared.
###end p 124
###begin title 125
TUNEL assay
###end title 125
###begin p 126
###xml 86 88 86 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
Tumor cell apoptosis was analyzed in bone metastases tissue sections using the DeadEndTM Colorimetric TUNEL system (Promega), according to the manufacturer's instructions.
###end p 126
###begin title 127
Statistical Analyses
###end title 127
###begin title 128
In Vivo
###end title 128
###begin p 129
###xml 472 474 470 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p&lt;</italic>
All data were analyzed with the use of Graphpad Prism v4.0 software (GraphPad Software, Inc., La Jolla, CA). Differences in osteolytic lesion area between clones and treatment groups were analyzed by two-way ANOVA. Histomorphometry for tumor burden and osteoclast number was analyzed by one-way ANOVA and Tukey's or Newman-Keuls multiple comparison test. Kaplan-Meier survival curve data was analyzed by a Logrank test. All the results were expressed as mean +/- SEM, and p<0.05 was considered significant.
###end p 129
###begin title 130
In Vitro
###end title 130
###begin p 131
###xml 309 311 307 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p&lt;</italic>
All data were analyzed with the use of Graphpad Prism v4.0 software (GraphPad Software, Inc., La Jolla, CA). Samples were analyzed in triplicate for RT-PCR, dual-luciferase assays, ELISA, and flow cytometry and statistics analyzed by unpaired t-test. Results are expressed as mean +/- standard deviation, and p<0.05 was considered significant. Immunostaining was analyzed by one-way ANOVA or unpaired t-test.
###end p 131
###begin title 132
Supporting Information
###end title 132
###begin p 133
###xml 25 30 <span type="species:ncbi:9606">human</span>
Sequences of primers for human genes analyzed by semi-quantitative RT-PCR.
###end p 133
###begin p 134
(0.04 MB DOC)
###end p 134
###begin p 135
Click here for additional data file.
###end p 135
###begin p 136
PCR primer sequences for 5' to 3' deletion of VEGF and CXCR4 promoters.
###end p 136
###begin p 137
(0.03 MB DOC)
###end p 137
###begin p 138
Click here for additional data file.
###end p 138
###begin p 139
The authors thank Chris McKibbin and Mary Riggins for their technical assistance.
###end p 139
###begin title 140
References
###end title 140
###begin article-title 141
Mechanisms of bone metastasis.
###end article-title 141
###begin article-title 142
Metastasis to bone: causes, consequences and therapeutic opportunities.
###end article-title 142
###begin article-title 143
TGFbeta in Cancer.
###end article-title 143
###begin article-title 144
Smad transcription factors.
###end article-title 144
###begin article-title 145
Molecular basis of metastasis.
###end article-title 145
###begin article-title 146
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
###end article-title 146
###begin article-title 147
Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways.
###end article-title 147
###begin article-title 148
A multigenic program mediating breast cancer metastasis to bone.
###end article-title 148
###begin article-title 149
Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
###end article-title 149
###begin article-title 150
###xml 75 80 <span type="species:ncbi:9606">human</span>
Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo.
###end article-title 150
###begin article-title 151
The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.
###end article-title 151
###begin article-title 152
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway.
###end article-title 152
###begin article-title 153
###xml 34 39 <span type="species:ncbi:9606">Human</span>
Stable Overexpression of Smad7 in Human Melanoma Cells Impairs Bone Metastasis.
###end article-title 153
###begin article-title 154
###xml 39 44 <span type="species:ncbi:10090">mouse</span>
Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo.
###end article-title 154
###begin article-title 155
Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor.
###end article-title 155
###begin article-title 156
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.
###end article-title 156
###begin article-title 157
Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.
###end article-title 157
###begin article-title 158
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
###end article-title 158
###begin article-title 159
Oxygen tension is an important mediator of the transformation of osteoblasts to osteocytes.
###end article-title 159
###begin article-title 160
Hypoxia-a key regulatory factor in tumour growth.
###end article-title 160
###begin article-title 161
Exploiting tumour hypoxia in cancer treatment.
###end article-title 161
###begin article-title 162
###xml 60 65 <span type="species:ncbi:9606">human</span>
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.
###end article-title 162
###begin article-title 163
Targeting HIF-1 for cancer therapy.
###end article-title 163
###begin article-title 164
###xml 107 112 <span type="species:ncbi:9606">human</span>
Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells.
###end article-title 164
###begin article-title 165
Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-beta.
###end article-title 165
###begin article-title 166
###xml 98 103 <span type="species:ncbi:9606">human</span>
Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.
###end article-title 166
###begin article-title 167
Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.
###end article-title 167
###begin article-title 168
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.
###end article-title 168
###begin article-title 169
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
###end article-title 169
###begin article-title 170
###xml 144 149 <span type="species:ncbi:9606">human</span>
Ki26894, a novel transforming growth factor-beta; type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
###end article-title 170
###begin article-title 171
###xml 141 147 <span type="species:ncbi:10090">murine</span>
###xml 152 157 <span type="species:ncbi:9606">human</span>
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
###end article-title 171
###begin article-title 172
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.
###end article-title 172
###begin article-title 173
2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
###end article-title 173
###begin article-title 174
###xml 90 94 <span type="species:ncbi:10116">rats</span>
The effect of 2-methoxyestradiol, a HIF-1 alpha inhibitor, in global cerebral ischemia in rats.
###end article-title 174
###begin article-title 175
###xml 61 66 <span type="species:ncbi:9606">human</span>
Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker.
###end article-title 175
###begin article-title 176
Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma.
###end article-title 176
###begin article-title 177
###xml 80 85 <span type="species:ncbi:9606">human</span>
HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors.
###end article-title 177
###begin article-title 178
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.
###end article-title 178
###begin article-title 179
###xml 63 68 <span type="species:ncbi:9606">human</span>
Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I.
###end article-title 179
###begin article-title 180
###xml 54 59 <span type="species:ncbi:9606">human</span>
Genomic organization and promoter characterization of human CXCR4 gene.
###end article-title 180
###begin article-title 181
Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha.
###end article-title 181
###begin article-title 182
2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo.
###end article-title 182
###begin article-title 183
Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies.
###end article-title 183
###begin article-title 184
Risks and benefits of bisphosphonates.
###end article-title 184
###begin article-title 185
Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone.
###end article-title 185
###begin article-title 186
Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
###end article-title 186
###begin article-title 187
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
Mechanisms underlying TGF-beta1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis.
###end article-title 187
###begin article-title 188
###xml 88 93 <span type="species:ncbi:9606">human</span>
Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression.
###end article-title 188
###begin article-title 189
Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression.
###end article-title 189
###begin article-title 190
The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis.
###end article-title 190
###begin article-title 191
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse 4T1 breast tumor model.
###end article-title 191
###begin article-title 192
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications.
###end article-title 192
###begin article-title 193
Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone.
###end article-title 193
###begin article-title 194
T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.
###end article-title 194
###begin article-title 195
###xml 70 76 <span type="species:ncbi:10090">Murine</span>
Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma-Associated Bone Loss.
###end article-title 195
###begin article-title 196
Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
###end article-title 196
###begin article-title 197
###xml 111 115 <span type="species:ncbi:10116">rats</span>
Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI.
###end article-title 197
###begin article-title 198
Mechanism of action of 2-methoxyestradiol: new developments.
###end article-title 198
###begin article-title 199
New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent.
###end article-title 199
###begin article-title 200
Pharmacologic inhibition of the tgf-Beta type I receptor kinase has anabolic and anti-catabolic effects on bone.
###end article-title 200
###begin article-title 201
The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development.
###end article-title 201
###begin article-title 202
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Enhanced bone regeneration associated with decreased apoptosis in mice with partial HIF-1alpha deficiency.
###end article-title 202
###begin article-title 203
Hypoxia is a major stimulator of osteoclast formation and bone resorption.
###end article-title 203
###begin article-title 204
Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia.
###end article-title 204
###begin article-title 205
Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.
###end article-title 205
###begin article-title 206
Acute hypoxia and osteoclast activity: a balance between enhanced resorption and increased apoptosis.
###end article-title 206
###begin article-title 207
Bone loss and fracture risk associated with cancer therapy.
###end article-title 207
###begin article-title 208
###xml 93 96 <span type="species:ncbi:10116">rat</span>
Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat.
###end article-title 208
###begin article-title 209
VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism.
###end article-title 209
###begin article-title 210
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells.
###end article-title 210
###begin article-title 211
###xml 89 94 <span type="species:ncbi:9606">Human</span>
Evidence for a Causal Role of Parathyroid Hormone-related Protein in the Pathogenesis of Human Breast Cancer-mediated Osteolysis.
###end article-title 211
###begin article-title 212
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.
###end article-title 212
###begin p 213
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 213
###begin p 214
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by a Department of Defense (DoD) predoctoral fellowship (BC073157) and University of Virginia Medical Scientist Training Program (T32-GM007267) and Ruth L. Kirschstein National Research Service Cancer Training (T32-CA009109) fellowships to L.K. Dunn; grants from the Mary Kay Ash Foundation, National Institutes of Health (R01-CA69158) and DoD (PC040341) to T.A. Guise; DoD grant (PC051194) to J.M. Chirgwin; DoD postdoctoral fellowship (PC061185) to P.G.J. Fournier; the University of Virginia Cancer Center and the Gerald Aurbach endowment. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 214

